Characterizing the Cofactor Specificity of NQO2 by Al Massri, Shahed
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
6-1-2017 12:00 AM 
Characterizing the Cofactor Specificity of NQO2 
Shahed Al Massri 
The University of Western Ontario 
Supervisor 
Dr. Brian Shilton 
The University of Western Ontario 
Graduate Program in Biochemistry 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Shahed Al Massri 2017 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Biochemistry Commons 
Recommended Citation 
Al Massri, Shahed, "Characterizing the Cofactor Specificity of NQO2" (2017). Electronic Thesis and 
Dissertation Repository. 4586. 
https://ir.lib.uwo.ca/etd/4586 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
   
ii 
 
Abstract 
Quinone Reductase 2 (NQO2) is a part of an enzyme family implicated in detoxification 
of the cell. This enzyme differs from its highly similar sister protein Quinone Reductase 1 
(NQO1) by its unique cofactor preference for dihydro-nicotinamide riboside (NRH) instead of 
NADH. Cellular levels of NRH have not been characterized, contributing to the mystery 
surrounding the physiological role of NQO2. This project focused on identifying what 
determines the cofactor specificity of NQO2, and engineering it to use NADH instead of NRH. 
The investigation included optimization of protein purification, an in silico analysis that 
revealed the different stereochemistry of NQO2/1 from other flavoenzymes, and an x-ray 
analysis of crystallized NQO2 after NADH soak. An informed site-directed mutagenesis 
approach yielded a 70-fold increase in the catalytic efficiency of NQO2 utilizing NADH, 
compared to the wildtype. The results of this project help characterize the cofactor preference 
of NQO2 on a molecular level. 
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1 Chapter 1 – Introduction 
Mapping out a protein’s role in the cell is a very exciting process of research, and there are 
many proteins with yet undiscovered function in human cells. This project’s overarching goal 
was to characterize the cofactor specificity of NQO2, a member of a protein family called 
quinone reductases, in order to help shed some light on its physiological role in the cell. The 
main purpose of this protein was thought to be detoxification of the cell through quinone 
reduction; however recent discoveries suggest that NQO2 may serve a signaling function 
beyond its redox mechanism. This hypothesis came about in part due to the fact that NQO2 
uses a unique cofactor as an electron donor, dihydro-nicotinamide riboside (NRH), which is not 
utilized by any other proteins including related quinone reductase isoforms. This unique 
cofactor preference is a double-edged sword, suggesting the possibility of a signaling role for 
NQO2 but also being a source of difficulty in studying its in vivo contributions. In this research 
project, I have used a molecular-based approach to examine the cofactor specificity of NQO2 
towards NRH as a stepping stone towards discovering its cellular role beyond the reduction of 
quinone compounds. 
1.1 Quinones and quinone reductases 
1.1.1 Quinones 
Quinones are cyclic conjugated organic compounds abundantly found in living cells, 
serving a variety of functions such as electron acceptors and cofactors in protein mechanisms. 
Despite their importance in the cell, they are prone to forming radical intermediates named 
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semi-quinones, which are produced through a one-electron reduction (Figure 1). Semi-
quinones can be formed spontaneously or through one-electron reductases (1). These radicals 
are highly unstable, and can react with oxygen to form superoxide species that are extremely 
reactive and therefore damaging to the cell. Quinone reductases prevent the formation of these 
harmful radicals by regulating the abundance of quinones through performing a two-electron 
reduction on them (2), resulting in the fully reduced hydroquinone form that is much less prone 
to auto-oxidation (3). This mechanism is the reason quinone reductases are considered members 
of the detoxification infrastructure that protects the cell from oxidative stress. It is believed that 
quinones existed in the environment and unicellular organisms from a very ancient time – as far 
as 2 billion years ago – which is why the QR family is also believed to be similarly ancient (4). 
There was likely strong selection pressure for an enzyme that prevents cellular damage from 
semi-quinone formation.  
 
Figure 1: A two-electron reduction versus a one-electron reduction of quinones. 
A one electron reduction results in the radical intermediate semi-quinone, while a two-electron 
reduction catalyzed by quinone reductases results in hydroquinone. 
1.1.2 Quinone reductases 
Quinone reductases (QRs) are a family of proteins ubiquitously found in both 
prokaryotic and eukaryotic cells. The earliest identified forms of QRs were originally dubbed 
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DT-diaphorases, stemming from their ability to utilize both NADH and NADPH as cofactors 
(1). The first QR was identified in rat liver, and is now referred to as NQO1. The “NQO” 
nomenclature is usually used for the vertebrate isoforms of these proteins, and they are 
expressed in varying levels amongst different tissues. One of the key characteristics of quinone 
reductases is a tightly-linked flavin molecule, which is critical for electron movement from 
cofactor to substrate in the reduction mechanism utilized by QRs (5). In the case of the 
vertebrate isoforms (NQO1, NQO2) this co-enzyme is flavin adenine dinucleotide (FAD), 
while in most other species (e.g. bacterial, yeast) it is flavin mononucleotide (FMN). With the 
exception of a few protein variants in plants and fungi, quinone reductases use a ping-pong 
mechanism to transfer two electrons from their respective nicotinamide cofactor (NADH, 
NADPH, NRH) to the flavin co-enzyme present in the protein. Once this occurs, the oxidized 
cofactor dissociates and the electrons are donated from the reduced flavin to the newly bound 
quinone substrate, thus concluding the ping-pong reduction mechanism. 
QRs exist in dimeric or tetrameric forms. The mammalian isoforms of NQO1 and 
NQO2 are dimers. FAD molecules (one for each catalytic site) are non-covalently bound at the 
interface of the two monomers, situated at the bottom of an intermolecular cavity that serves as 
the catalytic site (Figure 2). There are several inter-molecular interactions (H-bonds, salt 
bridges) between the two monomers at the interface that offer great stability to the dimer, with a 
total interface area of ~2,700 Å2 in NQO1 (6). The two catalytic sites in QRs are identical, and 
accommodate both the electron-donating cofactor and the electron-accepting substrate at 
different stages of the reduction mechanism. Residues from both monomer chains participate in 
the binding and enzymatic process at each catalytic site. 
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Figure 2: Catalytic sites in NQO1 and NQO2. 
The NQO2 (left) and NQO1 (right) catalytic site cavities at the dimer interface, visualized by a 
surface representation of the crystal structures 1QR2 (NQO2) and 1D4A (NQO1) (7, 8). FAD 
molecule shown in yellow carbons. The monomeric units in each dimeric protein are 
highlighted in different colours. The bridge appearing over the FAD molecule in proximity to 
the catalytic cavity in NQO2 (left) is created by a hydrogen bond between the residues E193 
and N66. Visualized in PyMOL (9). 
1.2 A comparison of the similarities and differences 
between NQO1 and NQO2 
The regulation and direct role of NQO2 in the cell have not been characterized as well 
as the sister protein NQO1. For this reason, a comparison between the two proteins is 
informative for elucidating the involvement of NQO2 in cellular functions. It is quite 
interesting that two sister proteins that share high structural, sequence, and mechanism 
similarity will reduce distinctly different cofactors and substrates. The role of NQO1 as a 
cytoprotective enzyme has been strongly supported through: the wide variety of chemicals 
that induce its activity, the fact that raising/lowering the protein’s levels was associated with 
respectively decreased/increased susceptibility of the cell to oxidative stress, and its 
regulation through the Keap1/Nrf2/ARE pathway alongside other detoxifying genes (10). 
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On the other hand, there is limited knowledge of the regulation of NQO2 and the identity of 
its endogenous substrates in the cell. Comparing the similarities and differences between 
NQO2 and NQO1 was important for this project, as the differences between them were used 
to inform the approach for characterizing the unique cofactor preference of NQO2. 
1.2.1 Similarities between NQO1 and NQO2 
“NQO1” and “NQO2” hereafter refer to their mammalian isoforms within the quinone 
reductase family of enzymes. They are both dimeric, cytosolic proteins that are ubiquitously 
expressed in mammalian tissue, and their subunits are 274 and 231 residues in length 
respectively (11). Their subunit molecular weights are 30,880 and 25,956 Da respectively.  The 
structures of NQO1 and NQO2 are highly similar (Figure 3); as would be expected with 46% 
identity between the two sequences (Figure A- 1, Appendix A). A structural alignment in 
PyMOL reports an RMSD of 0.808 Å between the backbones of NQO2 and NQO1, which 
indicates high structural similarity between the two proteins. Both proteins contain a tightly-
linked FAD molecule in each active site, which accepts electrons from their respective 
cofactors and subsequently reduce the substrate molecule.  
Interestingly, there is strong evidence to suggest that NQO1 and NQO2 are involved in 
the p53 apoptosis signaling pathway of the cell (12, 13). For example, NQO2 was found to be 
the only human protein target of the antimalarial drug chloroquine, and chloroquine has been 
shown to activate the p53 pathway, but the process through which this occurs is unknown (14, 
15). This led to the hypothesis that NQO2 is at least partially responsible for the off-target 
effects of chloroquine on p53 activation, and that NQO2 is involved in apoptosis signaling (see 
also section 1.6). Although the specific pathways by which these proteins are influencing p53 
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have not been characterized, there is accumulating evidence suggesting their involvement. The 
fact that these enzymes may serve an important cell signaling role beyond their detoxification 
task would be unusual, which is the reason they became the focus of this project. Characterizing 
their involvement in the p53 pathway would be highly intriguing due to the importance of p53 
in apoptosis and tumor suppression. 
1.2.2 Differences between NQO1 and NQO2 
Although NQO1 and NQO2 share many similarities, they are specific to different 
cofactors, substrates, and are targeted by different inhibitors. Inhibitors of NQO1 such as 
phenindione, dicoumarol and Cibacron Blue do not inhibit NQO2 (16). Unique inhibitors of 
NQO2 include chloroquine, quinacrine, primaquine and resveratrol (14, 17).  
The difference between NQO1 and NQO2 that is most relevant for this project is the 
cofactor used in their reduction mechanism. NQO1 can use either NADH or NADPH as an 
electron donor (18). In the case of NQO2, it uses reduced nicotinamide riboside (NRH) (Figure 
4). There is a great deal of mystery surrounding NRH and its role in the cell, as NQO2 is the 
only enzyme known to utilize it as a cofactor (19). It is hypothesized to be a breakdown product 
of NADH because it has been observed in tissue extracts (20), but the cellular conditions which 
induce formation of NRH are unknown. It is worth noting that noticeable amounts of its 
oxidized form (NR) were observed in rat liver to arise from the enzymatic breakdown of NAD 
and NADP, the oxidized forms of NADH and NADPH (21). 
The most noticeable structural difference between NQO1 and NQO2 is the presence of a 
flexible 43-residue C-terminal tail in NQO1 (Figure 3). This is considered a unique feature to 
NQO1 since it is not found in any other quinone reductase family members, such as the 
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bacterial and yeast isoforms. Originally this C-terminal tail did not resemble any known 
domains and was considered non-catalytic (5). However, upon removal of this C-terminal 
domain it was reported that the catalytic efficiency of NQO1 decreased from 440 to 1.2 min-1 
µM-1, suggesting that it serves an important role in the mechanism of NQO1 (22, 23). 
Interestingly the presence of this tail does not correlate with the enzyme preference to 
NAD(P)H versus NRH, for example the yeast isoform Lot6p and the bacterial isoform AcpD do 
not contain this C-terminal portion but still primarily utilize NADH/NADPH (24). The C-
terminal tail was hypothesized to be partially responsible for NAD(P)H binding stabilization in 
NQO1 due to an observed interaction of Phe-232 in the tail with bound NADPH (25).  
 
Figure 3: Superimposed cartoon representation of the backbones of NQO1 and NQO2. 
NQO1 is shown in blue, while NQO2 is in magenta. Panels A and B show the protein from two 
different sides, rotated 180°. One of the main differences in the two proteins’ structures is the 
presence of 43-residue C-terminal in NQO1, which is not present in NQO2. This C-terminal tail 
can be seen in Panel B, highlighted in dark blue. 
While NQO2 has a much higher affinity for NRH over NADH, it has been observed to 
utilize NADH weakly as a cofactor, and the same for NQO1 utilizing NRH (23). The fact that 
NQO2 is capable of binding NADH in a productive manner was another important point to 
consider for this project, since the goal was to shift its cofactor specificity from NRH to NADH.  
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Figure 4: Structures of NADPH, NADH and NRH. 
NADPH (left) and NADH (middle) are cofactors used by NQO1. NRH (right) is used by 
NQO2.  
The kinetic parameters previously reported by Chen et al. for the two proteins with each 
cofactor are listed in Table 1. In a previous attempt to change the specificity of NQO2 to 
NADH (and NQO1 to NRH), a tail-less NQO1 as well as a chimeric NQO2 with the tail added 
were created (23). These modified proteins were assayed to determine whether the tail is 
responsible for the specificity of each protein towards their respective cofactors. The kinetics 
results showed that NQO1 functions significantly worse without its C-terminal tail, reporting a 
300-fold decrease in catalytic efficiency using NADH, and a 20-fold decrease in its (already 
poor) efficiency using NRH. However, the results showed that removal/addition of the tail did 
not cause significant change in either protein’s cofactor preference. This eliminates the 
possibility that the tail is responsible for the proteins’ selectivity towards their respective 
cofactors, and suggests that there are more subtle elements at hand. It is not surprising that the 
C-terminal tail in NQO1 is not solely responsible for its preference towards NAD(P)H over 
NRH, since other NQO1 isoforms utilizing the same cofactor do not possess this tail region. 
However, the work done by Chen et al. (23) provides an excellent background for this project 
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since we were able to focus our attention on the NQO2 active site itself without having to 
consider whether the tail portion is partially responsible for the enzymes’ cofactor preference. 
Table 1: Previously published kinetic parameters for NQO1 and NQO2, using NRH or 
NADH as a cofactor 
Kinetic paramaters for NQO2 
   NRH NADH 
 Km (µM) 28 330 
 
kcat (min-1) 2700 35 
 
kcat /Km (min-1µM-1) 96 0.1 
       
 Kinetic paramaters for NQO1 
   NRH NADH 
 Km (µM) 440 70 
 
kcat (min-1) 1680 30,900 
 
kcat /Km (min-1µM-1) 3.8 440 
 *Kinetic data in this table is reported from work by Chen et al. (23)  
NQO2 contains one surface zinc binding site per monomer, which NQO1 does not 
possess (7). This zinc binding site exists approximately 10 Å from the active site. Past research 
shows that addition of zinc or copper (1 mM) did not have an effect on the activity of NQO2 
(26). In addition, extensive dialysis of NQO2 against 100 mM EDTA as well as addition of 100 
mM EDTA into the reaction solution did not significantly affect NQO2 activity, suggesting that 
the metal is not required for the enzyme’s catalytic function (26). Some bacterial isoforms as 
well as common ancestors of NQO1 and NQO2 also possess this zinc binding site, but they do 
not share the specificity of NQO2 towards NRH. 
The NQO1 and NQO2 active sites are quite similar with the exception of a few residues. 
A visualization of the surface of the two protein’s active sites shows that the region around the 
binding cavity appears more restricted in NQO2, largely due to a hydrogen bond between E193 
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and N66 that forms a “bridge” over the FAD molecule (Figure 2). On the other hand, the 
differences in residues within the active site itself (directly above the isoalloxazine ring 
structure of the FAD molecule) result in a slightly larger and more hydrophobic binding pocket 
in NQO2 compared to NQO1 (5).  
1.3 Reaction mechanism of NQO1 and NQO2 
 
Figure 5: The ping-pong reaction mechanism of NQO1 and NQO2. 
Two electrons are transferred from NRH to FAD, reducing it to FADH2 and changing the 
overall protein’s conformation to its reduced form (highlighted in green). The reduced NQO2-
FADH complex can reduce quinones by transferal of two electrons. In the case of NQO1, NRH 
is replaced by NAD(P)H, which is oxidized to NAD(P). 
Both proteins perform their reduction through a similar ping-pong mechanism (Figure 5). 
For NQO2, an NRH molecule will bind the active site and donate two electrons to the FAD 
molecule, reducing it to FADH2. In previous work determining the reduced conformation of the 
enzyme, it was observed that the isoalloxazine ring of FAD acquires a 4-5° bend upon 
reduction, changing the overall conformation of the enzyme alongside it (19). This new 
conformation is hereafter referred to as the “active” or “reduced” form of NQO2, which is 
assumed to be an intermediate conformation of the protein upon receiving electrons from the 
cofactor. Once NR dissociates from the binding site, the enzyme can bind and reduce its 
quinone substrate to a hydroquinone (also referred to as quinol) and once again return to its 
oxidized form. This mechanism is the same in NQO1, with the exception of utilizing NADH or 
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NADPH instead of NRH. NQO1 does not significantly discriminate between NADH and 
NADPH; the rates of NQO1 reduction by NADPH and NADH were reported to be 11.3 x 108 
and 8.8 x 108 M-1 min-1 respectively (27). 
1.4 NQO1 and NQO2 knockout experiments  
Knocking out a protein of interest can be quite useful in elucidating its physiological role in 
the cell. Any subsequent changes in the cell’s phenotype can indicate which cellular processes 
the protein participates in. There have been several knockout experiments performed on 
quinone reductases, which have not conclusively demonstrated the processes NQO2 is involved 
in, but are important to consider for furthering the characterization of its role in the cell. 
The yeast isoform Lot6p shares 21% sequence identity with NQO1, with a similar structure 
and quinone reduction mechanism utilizing NAD(P)H as a cofactor (5). Quinone reductases 
have been proposed to participate in the oxidative stress response, hence the effects of Lot6p 
knockout and overexpression were monitored under hydrogen peroxide-induced apoptosis (28). 
It was shown that Lot6p knock-out strains had a deficiency in apoptotic cell death compared to 
the wildtype, while overexpression resulted in enhanced levels of cell death. This implies a 
direct involvement of Lot6p in apoptotic cell death caused by oxidative stress in yeast. 
When NQO1 or NQO2 was knocked out in mice, no effects on birth and reproduction 
were observed (29). However, the NQO2-knockout mice exhibited myeloid hyperplasia in their 
bone marrow. NQO1 deficient mice were more sensitive to hepatic toxicity induced by 
menadione than the wildtype, suggesting that NQO1 helps protect against menadione toxicity 
(30). Menadione (vitamin K3) is a quinone compound which is a substrate for both NQO2 and 
NQO1. NQO2 deficient mice on the other hand were less sensitive to menadione’s effects, 
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suggesting that NQO2 plays a role in activation of menadione toxicity (11). In contrast, by 
comparing cells overexpressing NQO2 with wildtype and NQO2-deficient cells, it was found 
that NQO2 is an activator of the quinones Mitomycin C and BP-3,6-Q, and the anti-tumor drug 
CB1954 (31). This was reinforced by the fact that the cellular toxicity of these drugs was 
significantly higher in the presence of NRH in the medium, which is required for NQO2 
activity. 
In an experiment to investigate the role of NQO2 in protection against radiation-
triggered oxidative stress, NQO2-knockout mice were shown to have higher susceptibility to 
myeloproliferative diseases induced by γ-radiation (32). NQO2 was shown to participate in 
protection against γ-radiation by preventing the degradation of myeloid differentiation factors 
by the 20S proteosome. The transcription factor C/EBPα is crucial for differentiation of 
immature granulocytes, and possesses a recognition sequence for degradation by the 20S 
proteasome. The study found that NQO2 competes with the 20S proteasome for that same 
binding sequence, thus protecting C/EBPα from degradation. Upon exposure of the mice to γ-
radiation, NQO2 abundance and activity rose higher which led to decreased proteosomal 
degradation of C/EBPα and higher levels of NQO2 and C/EBPα interaction. These findings 
imply that NQO2 plays a significant role in prevention of some hematological disorders. This 
effect was shown to be independent of NQO1’s presence in the cell. 
It is worth noting that while the studies using NQO2-knockout mice showed that the 
mice exhibited myeloid hyperplasia (11) and increased susceptibility to certain carcinogens 
(29), other studies using imatinib treatments (found to be an off-target inhibitor of NQO2) did 
not observe these side-effects (33). The cellular function of NQO2 is yet to be fully deduced, 
considering that the origins and role of NRH in the cell remains a mystery.  
13 
 
One reason that knockout experiments with NQO2 are difficult to interpret for 
determining its physiological role is that the cellular conditions at which NRH is present are 
unknown. If it is unknown when NRH is available to allow NQO2 activity, it is difficult to 
determine the origin of the effects from knocking out the protein. This is one of the driving 
factors of this project, which aimed to create an NQO2 that uses the much better characterized 
NADH as a cofactor. If this was successful, the mutant NQO2 could be a significant boon for 
easier interpretation of the results of knockout experiments, in addition to helping characterize 
the cofactor preference of NQO2. 
1.5 NQO1 and NQO2 common ancestry 
A phylogenetic analysis of NQO1 and NQO2 revealed a common ancestor in ancient 
eubacteria which was dubbed ‘NQO3” (4). We have used 33 different NQO homologs (4 
bacterial ancestor NQO3 and 29 from NQO1/NQO2 isoforms found in vertebrates) to create a 
phylogenetic tree that illustrates the proteins’ commen ancestry (Figure 6). This NQO3 
nomenclature is not to be confused with the “NQO” prefix used for the vertebrate isoforms, but 
rather chosen to showcase that it is an  evolutionary ancestor of these protein variants. These 
ancestral proteins are not fully characterized, but a few sequence-derived properties have been 
identified. NQO3 enzymes use NAD(P)H as a cofactor (34), which is interesting because it 
implies NQO2 diverged as an NRH-dependent protein likely due to evolutionary pressure 
towards fulfilling a task that the NADH-dependent quinone reductases did not serve. As for the 
43-residue C-terminal tail found in NQO1, the NQO3 proteins did not include such a region. 
This property remains unique to NQO1, and suggests that it may serve a function that appears 
unrelated to the preference towards NAD(P)H. Some of the NQO3 sequences reveal a zinc-
binding site, which is also found in NQO2 but not in NQO1. 
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Figure 6: Phylogenetic tree showcasing NQO1 and NQO2 common ancestry. 
Phylogenetic calculation in MrBayes and phylogeny.fr (35, 36) including 33 NQO sequences, 
four “NQO3” from eubacteria and the remainder sequences are from various NQO1/NQO2 
isoforms found in vertebrates 
1.6 Evidence towards the involvement of NQO1 and 
NQO2 in p53-signalling pathways 
 An interesting facet of both NQO1 and NQO2 is their possible connection to the 
apoptosis signaling pathway of the cell through the transcription factor p53. NQO1 was shown 
to be involved in the stabilization of p53 in an experiment where inhibition of NQO1 by 
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dicoumarol resulted in a decrease in p53 levels due to its degradation (12). It was observed that 
when NQO1 was overexpressed in colon carcinoma cells, p53 levels remained stable despite 
addition of dicoumarol.  It was also observed that induction by oxidative stress resulted in the 
highest levels of NQO1-mediated stabilization of p53. These data strongly supports a role for 
NQO1 in apoptosis-signaling through stabilization of p53 against degradation. 
Another connection between NQO1 and NQO2 and p53 activation was established in an 
experiment that measured accumulation of p53 due to exhaustion of pyrimidine nucleotides in 
the cell (13). It was previously known that p53 was activated by a mitochondrial signal from the 
electron transport chain (ETC), but the mechanism was unknown. By inhibiting different 
components of the ETC, it was found that p53 stabilization occurred when complex III 
inhibitors were used, resulting in depletion of pyrimidines in the cell. However, this effect was 
abrogated when NQO1 and NQO2 were removed using siRNA together with inhibition of 
complex III, implying that NQO1 and NQO2 play a key role in mitochondrial–induced 
stabilization of p53. NQO1 and NQO2 were also observed to co-localize with p53 from the 
cytoplasm to the nucleus. NQO1 and NQO2 are usually found in the cytoplasm, therefore it was 
unusual to observe them localizing elsewhere for a specific function. 
Although the connection between NQO2 and p53 is yet to be fully elucidated, there is more 
evidence which points to a potential role in facilitating p53 activity. NQO2 was identified by a 
proteomic approach to be one of the two protein targets of the anti-malarial drug chloroquine, 
the other protein being aldehyde dehydrogenase 1 (14). Of the two proteins, NQO2 was found 
to be the only one significantly inhibited by concentrations of chloroquine used in clinical 
treatment.  Chloroquine had previously been found to activate the p53 apoptosis pathway in 
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human glioblastoma cells (15). Since the drug inhibits NQO2, chloroquine’s involvement in the 
p53 pathway suggests a connection between NQO2 and p53. 
Chloroquine is used to treat diseases other than malaria, such as rheumatoid arthritis and is 
under investigation for use as a chemotherapy drug and to treat HIV-1/AIDS (37–39). 
Therefore, inhibition of NQO2 could be relevant in other types of diseases as well.  
Since NRH may be a breakdown product of NAD(P)H, and NQO2 is hypothesized to serve 
an apoptosis-related signaling function through p53, it is possible that NRH serves as a 
signaling molecule for apoptosis through NQO2. Exploring this potential function is of great 
interest to us, and it is the reason why this project was designed to help elucidate the 
physiological response that the NRH-driven activity of NQO2 may elicit in vivo. 
1.7 Project goals 
This project focused on determining why NQO2 has a preference for NRH over 
NAD(P)H; uncovering the molecular determinants for this cofactor specificity. If reduction of 
NQO2 through NRH acts as a molecular switch for p53, in vivo studies examining the cellular 
effect of NQO2 might provide some insight on its role in the pathway, and the signaling role of 
NRH. Since the cellular conditions at which NRH is present are not yet understood, the results 
of induction or knockout experiments are difficult to interpret for determining the cellular role 
of NQO2.   
Since the cellular abundance of NAD(P)H is well characterized (40–42), we speculate 
that engineering NQO2 to use NADH or NADPH instead may serve as a solution for 
elucidating its role in cell signaling. If the original function of the enzyme is retained in the 
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mutant NQO2, we predict that in vivo analysis of the physiological function of NQO2 would 
become significantly easier. For example, experiments involving knockout or elevated 
expression of NQO2 will be more conclusive, since the cellular levels of NAD(P)H are 
established and therefore it will be known when the mutant protein is active. Since the presence 
of the 43-residue C-terminal tail from NQO1 was not found to be responsible for either 
proteins’ cofactor preference (23), this investigation took a more specific approach to altering 
the cofactor specificity of NQO2, using site-directed mutagenesis informed by the binding site 
of NQO1. 
The molecular details of NRH binding within NQO2 (as well as NADH binding within 
NQO1) are unknown, which is the biggest obstacle for targeted mutagenesis aimed at changing 
its specificity to NRH. Based on the way NAD(P)H binds and donates electrons in other 
flavoenzymes, it was assumed that NRH binds NQO2 by similar stacking of the nicotinamide 
over the isoalloxazine ring of FAD.  N4 in the nicotinamide moiety directly stacks onto N10 of 
the isoalloxazine ring of FAD, bringing the two reducing sites from each molecule in close 
proximity for the electron transfer to occur. This process is characteristic of flavoenzymes (43). 
However, since a crystal structure of NQO2 with bound NRH has not been obtained, the 
residues involved in binding/catalysis have not been identified. The crystal structures available 
for NQO2 are the native protein (PDB ID: 1QR2), and several structures of NQO2 bound to 
inhibitors.  
It is important to note that although NQO2 has a preference for NRH, there is evidence 
that it can still utilize NADH as a reductant. The reverse is true for NQO1: it weakly utilizes 
NRH. In addition to the parameters obtained by Chen et al. (Table 1), it was observed that 
NQO2 metabolized the anti-tumor compound CB10-200 in the presence of 500 µM NADH, 
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also showing that NQO2 may be able to use NADH as a substrate to some extent (44). Another 
study also found that NQO2 can weakly utilize NADH, with a Km of approximately 300 µM 
(45). Thus, the cofactor specificity of the two proteins is not absolute. 
As previously mentioned, NQO1 does not readily discriminate between NADH and 
NADPH. If the cofactor specificity of NQO2 was successfully changed from NRH to 
NAD(P)H, similar affinities to both molecules may be observed. Cellular levels of NADH are 
usually low, with an NAD+/NADH ratio of 644 (41). On the other hand, relative NADPH 
levels are normally much higher, with an NADP+/NADPH ratio of about 0.01 (42) . Therefore 
determination and comparison of the affinities of the proposed mutant NQO2 for all three 
molecules is crucial. 
Our overall investigation into the cofactor specificity of NQO2 would help pave the way 
for addressing two topics. One of them is to help answer the question of how NQO2 evolved to 
use NRH. The other is that if the proposed mutant NQO2 uses NAD(P)H preferentially over 
NRH but still retains the original function of NQO2, it would be highly useful for in vivo 
determination of the role of NQO2, since it would be known when the protein is active. 
Uncovering the cellular function of NQO2 would be a big step forward towards elucidating 
what NRH may signal about state of the cell that would elicit the signal for apoptosis. 
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2 Chapter 2 – Materials and Methods 
FAD, bovine serum albumin (BSA), phenylmethanesulfonyl fluoride (PMSF), 
menadione, 3-(4,5-dimethylthiozol-2-yl)-2,5diphenyltetrazolium (MTT), reduced nicotinamide 
adenine dinucleotide (NADH) were purchased from Sigma-Aldrich. NaCl, Tris, HEPES, 
(NH4)2SO4 and NaH2PO4 purchased from EMD chemicals. Ampicillin, lysozyme, dithiothreitol 
(DTT) were purchased from Bioshop Canada. Full length human NQO1 cDNA clone was 
purchased from OriGene. Protein concentrations were determined using a Bradford assay with a 
BSA standard. All SDS-PAGE gels were stained with solution containing 0.5 g/L CoomassieTM 
Brilliant Blue. 
2.1 Cloning and site-directed mutagenesis 
Mutations were introduced to NQO2 using the protocol for site-directed mutagenesis 
QuikchangeTM by Stratagene (La Jolla, CA). The primers used are listed in Table 2. PProEx-
HTa (Invitrogen) plasmid containing full-length His-tagged human NQO2 was used as the 
template for site-directed mutagenesis. The PCR products were transformed into XL1B E. coli, 
and incubated overnight on plates containing ampicillin (0.1 mg/mL) in order to select for 
transformants. Colonies were picked, followed by plasmid extraction and sequencing to 
confirm the presence of the desired mutations. The extracted plasmid was then transformed into 
BL21 E. coli and grown overnight for expression and purification of the protein. 
Full-length human NQO1 cDNA clone (OriGene) was modified through mutagenic 
PCR to include restriction sites for NcoI and XbaI flanking the protein sequence, primers used 
are listed in Table 3. The primers allowed for an in-frame insertion of the protein sequence 
within the plasmid. The product was cloned into PProEx-HTa plasmid (also containing the 
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same restriction sites in its polylinker region) through digestion with NcoI and XbaI and 
subsequent ligation. The final construct includes a TEV protease cleavage site as well as a His-
tag upstream of the protein sequence. The nucleotide sequence for NQO1 was verified within 
the construct by sequencing, then transformed into BL21 E. coli cells for protein expression.  
Table 2: Primers used for site-directed mutagenesis of NQO2 
Table 3: Primers used for addition of flanking restriction sites to NQO1 sequence 
Forward primer (NcoI site) 5’-GAGCCATGGTCGGCAGAAG-3’ 
Reverse primer (XbaI site) 5’-GGCTCTAGATTATTATTTTCTAGCTTTGATCTGGTTGTC-3’ 
 
2.2 Protein expression and purification 
2.2.1 Expression and purification of proteins 
Recombinant human NQO2 and the mutant proteins were expressed and purified using 
previously described methods (46). NQO1 was also expressed and purified using the same 
methods.  
Primer Name Primer Sequence 
a199c_t201g 5'-CTTTCTAATCCTGAGGTTTTCCAGTATGGAGTGGAAACCCACG-3' 
a199c_t201g_antisense 5'-CGTGGGTTTCCACTCCATACTGGAAAACCTCAGGATTAGAAAG-3' 
c217g_a218t 5'-CAATTATGGAGTGGAAACCGTCGAAGCCTACAAGCAAAGG-3' 
c217g_a218t_antisense 5'-CCTTTGCTTGTAGGCTTCGACGGTTTCCACTCCATAATTG-3' 
c367g_a368g 5'-GGATAGGGTGCTGTGCGGGGGCTTTGCCTTTGAC-3' 
c367g_a368g_antisense 5'-GTCAAAGGCAAAGCCCCCGCACAGCACCCTATCC-3' 
a385t_t386a_c387t 5'-CCAGGGCTTTGCCTTTGACTATCCAGGATTCTACGATTCCG-3' 
a385t_t386a_c387t_antisense 5'-CGGAATCGTAGAATCCTGGATAGTCAAAGGCAAAGCCCTGG-3' 
a581g_ 5'-GATCAGCTTTGCTCCTGGAATTGCATCCGAAGAAG-3' 
a581g_antisense 5'-CTTCTTCGGATGCAATTCCAGGAGCAAAGCTGATC-3' 
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BL21 E. coli cells transformed with the recombinant plasmid containing the respective His-
tagged protein were grown in auto-induction media as described by Studier (47).  Ampicillin 
(0.1 mg/mL) was included in the culture media in order to select for cells expressing the desired 
plasmid. The cell culture was incubated in four identical 1-litre media flasks for 19 hours at 
37°C while shaking at 220 RPM. Cells were harvested by centrifuging at 6,000 RPM for 10 
minutes in JLA-8.1 Rotor, and re-suspending the pellets in 50 mL of 50 mM phosphate buffer 
500 mM NaCl pH 7.5. Harvested cells were flash frozen at - 80°C then thawed and lysed by 
French press the next day after addition of 1 mM PMSF.  The cell lysate was applied to a 20 
mL Ni2+-bound Chelating Sepharose Fast Flow column, and NQO2 was eluted by raising 
imidazole concentration from 20 to 500 mM. After His-tag cleavage using tobacco etch virus 
(TEV) protease and 5 mM DTT, the protein was dialyzed overnight to decrease salt 
concentrations in preparation for anion exchange. The protein was applied to a 1.6 x 15-cm Q-
Sepharose HP (GE Healthcare) anion exchange column and eluted with a NaCl gradient from 0 
to 500 mM over a volume of 200 mL.  The Q-Sepharose column was equilibrated with 50 mM 
Tris-HCl pH 8. NQO2 containing fractions were pooled and concentrated to a volume of 5 mL, 
and treated with guanidine-HCl and FAD to final concentrations of 3M and 10 µM respectively. 
Denaturation with guanidine-HCl and allowing it to refold in the presence of FAD during size 
exclusion chromatography was performed for the purpose of fully reconstituting the protein 
with FAD rather than FMN. A 2.6 x 65-cm Superdex 200 (GE healthcare) size-exclusion 
column was equilibrated with 50 mM Tris-HCl 150 mM NaCl 10 µM FAD pH 8, and the 
concentrated protein was applied and resolved at a flow rate of 2 mL/min. Full reconstitution of 
FAD within the purified proteins was confirmed through absorbance measurements at 273 and 
450 nm according to previous methods (46). 
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2.2.2 Modification to purification protocol by DTT addition 
A modification to the above purification protocol was the addition of 10 mM DTT into 
the guanidine-HCl denaturation step to prevent misfolding of the protein during the gel 
filtration. After incubating on ice for 5 minutes, the protein solution was applied to a Superdex-
200 column equilibrated with 50 mM Tris-HCl  150 mM NaCl 10 µM FAD (pH 8.0). Fractions 
containing NQO2 were pooled, concentrated to 25 mg/mL, aliquoted, flash frozen and stored at 
-80 °C for crystallization and analysis. 
2.3 Crystallization and diffraction data collection of NQO2 with 
NADH 
Purified wildtype NQO2 at a concentration of 25 mg/mL was crystallized by hanging 
drop diffusion (drop volume of 1 µL) against reservoirs containing 0.1 M HEPES and 
concentrations of (NH4)2SO4 ranging from 1.2-2.2 M, at pH 7, 7.5 and 8. NQO2 was co-
crystallized with 10 mM NADH by mixing 0.5 µL of 20 mM NADH solution to 0.5 µL of 
concentrated protein into the tray well.  Crystals were soaked for 1 minute in 2 µL of 20% 
glycerol, 2 M (NH4)2SO4, 0.1 M HEPES pH 7.5 and 10 mM NADH, and the colour of the 
crystal was observed to change from yellow to clear. The crystal was then flash frozen and 
mounted for data collection. 
Diffraction data were collected using a rotating anode source emitting X-rays at a 
wavelength of 1.5418 Å. Data were processed using MOSFLM (48) and merged using Scala-
CCP4 (49).  Protein structure was solved using molecular replacement with 1QR2 as the 
starting model. Data was refined using PHENIX (50). 
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2.4 Absorbance spectrum collection of NQO1, wildtype 
NQO2, triple mutant and quintuple mutant 
Solutions of purified NQO1, wildtype NQO2, triple and quintuple mutant were diluted in 
Tris-HCl pH 8.0 and dialyzed using the same buffer. The solutions’ final concentrations were 
measured by Bradford assay. After baseline correction using the dialysis buffer, an absorbance 
spectrum was measured from 250 to 500 nm in a Cary 100-Bio spectrophotometer (Varian). 
The obtained spectra were scaled to correspond to 1 mg/mL based on the concentrations 
determined by the Bradford assay. 
2.5 CD Data collection 
Circular dichroism scans were obtained using a Jasco J-810 spectropolarimeter. A cell with 
path length of 0.1 mm was filled with protein solution diluted with buffer (20 mM sodium 
phosphate, 100 mM NaCl, pH 7.5). The protein was dialyzed in the buffer prior to 
measurement, and the buffer used in the dialysis was used to blank the instrument. The exact 
concentration of each protein solution was measured by Bradford assay in triplicate. The scans 
were performed at 20° C at 0.5 nm intervals from 190 to 260 nm. The data were normalized 
into molar ellipticity (ϴMRE) values using the concentrations obtained by the Bradford assays. 
2.6 Thermal denaturation curves 
Thermal denaturation scans were obtained using a Jasco J-810 spectropolarimeter. A cell 
with a volume of 300 µL and a path length of 1 mm was used for the measurements. The 
protein was dialyzed and diluted in the same buffer as the circular dichroism scans (above), and 
the protein concentrations were measured by Bradford assay. The scans were performed at 220 
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nm from 20° C to 90° C at a temperature increase rate of 1 degree per minute. The data were 
normalized into molar ellipticity (ϴMRE) values using the concentrations obtained by Bradford 
assay. The data were fit to Equation 1 with GraphPad Prism 4 software, using a linear 
extrapolation method adapted from previous work (51, 52). In this equation, x is the 
temperature in Kelvin, mn and md are the slopes of the native and denatured baselines 
(respectively) while yd and yn are the respective y-intercepts of those baselines. Tm is the 
inflection point and represents the melting temperature at which the protein is 50% denatured. 
R is the gas constant in units of kcal/mol•K, and ΔHm is the enthalpy of unfolding at the Tm in 
kcal/mol. This equation provides a calculation of the Tm from the data obtained in the thermal 
denaturation assay as well as an analysis of the fit of the melting curves. 
Equation 1: Linear extrapolation equation used for fitting thermal denaturation curves 
𝒚 =  
(𝒚𝒏 +  𝒎𝒏𝒙) + (𝒚𝒅 + 𝒎𝒅𝒙)𝒆𝒙𝒑 [
𝜟𝑯𝒎
𝑹
(
𝟏
𝑻𝒎
−
𝟏
𝒙
)]
𝟏 + 𝒆𝒙𝒑 [
𝜟𝑯𝒎
𝑹
(
𝟏
𝑻𝒎
−
𝟏
𝒙
)]
 
2.7 Enzyme kinetics using NADH as a cofactor 
Enzyme kinetics were obtained using a Cary 100-Bio spectrophotometer (Varian). 
Measurements were done under stirring in a 4.5 mL cuvette with a final volume of 2 mL. The 
components of the reaction solution were enzyme (NQO1, wildtype NQO2, triple mutant or 
quintuple mutant), menadione, MTT, NADH and Tris-HCl pH 8 buffer. MTT and menadione 
concentrations were kept constant in each reaction at 241 µM and 10 µM respectively. The 
reaction was monitored at 610 nm following addition of enzyme. Reduced menadione will 
reduce MTT in a non-catalyzed reaction, thus a change in absorbance corresponds to change in 
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levels of reduced MTT which indicates the enzymatic rate of menadione turnover using NADH 
as a cofactor. The reactions were performed at 20 °C. An MTT extinction coefficient of 11.3 x 
103 M-1 cm-1 was used to convert the rate of change in absorbance into moles of menadione 
reduced per minute. 
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3  Chapter 3 – Results 
3.1 Introduction 
The main goal of this project is to ultimately shed some light on why NQO2 has a 
preference for NRH over NAD(P)H. Since the sister protein NQO1 as well as other 
flavoenzymes (FAD-dependent oxidoreductases) typically utilize NADH and/or NADPH as 
electron donors, the goal was to identify the factors which determine the cofactor specificity of 
NQO2 for NRH over NAD(P)H. The first line of thought would be that NAD(P)H is a bigger 
molecule than NRH and is unable to bind within the active site of NQO2 due to steric 
hindrance. However; past research has shown that NQO2 can weakly utilize NADH (Table 1). 
This implies that NAD(P)H binding is possible within NQO2. Considering the fact that the two 
enzymes’ active sites are highly similar, the factors that determine its preference for NRH are 
likely subtle. By attempting to shift the cofactor specificity of NQO2 to NAD(P)H using site-
directed mutagenesis, I hope to not only address the molecular factors that give NQO2 this 
unique preference, but also generate a mutant NQO2 that could be utilized in future in vivo 
studies investigating the protein’s signaling role. A mutant NQO2 that utilizes NAD(P)H 
instead of NRH could be highly useful for such studies, as the cellular levels of NAD(P)H are 
much better characterized. 
The molecular details of NRH binding within NQO2 (as well as NADH binding within 
NQO1) are unknown, creating an obstacle for targeted mutagenesis aimed at changing its 
specificity to NRH. Based on the way NAD(P)H binds and donates electrons in other 
flavoenzymes, it is assumed that NRH binds NQO2 by similar stacking of the nicotinamide 
over the isoalloxazine ring of FAD. However, the residues involved in binding/catalysis are not 
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known, as a crystal structure with bound NRH has not been obtained. The sister protein NQO1, 
which shares 46% sequence identity with NQO2, is a great resource for a site-directed approach 
to modify the specificity of NQO2 without knowing the exact molecular aspects of binding. 
The fact that NQO1 utilizes NAD(P)H despite sharing high structural similarity with NQO2 
implies that the determinants of their specificity are subtle, and can be feasibly identified 
through site-directed mutagenesis. By directly comparing the active sites of the two proteins, I 
have chosen five different residues to mutate that significantly differ in their physicochemical 
properties.  
3.2 Selecting the mutation sites, creating the mutants and 
characterizing their effects compared to wildtype NQO2 and 
NQO1 
The target residues were mutated to the corresponding ones found in NQO1. A triple mutant 
dubbed NQO2-trp (Q122G, H72V, I128Y) and a quintuple mutant dubbed NQO2-qtp (Q122G, 
H72V, I128Y, E193G, N66Q) were constructed based on that comparison.  The two mutants as 
well as wildtype NQO1 and NQO2 were expressed and purified from E. coli, followed by an 
assessment of their structural integrity using circular dichroism. Kinetic assays comparing the 
cofactor specificity of these two mutants to the wildtype will pave the way towards more 
specific analysis using single mutants to assay each residue’s contribution to the observed 
change in cofactor specificity.  
3.2.1 Superimposition of NQO2 and NQO1 active sites revealed 
potential targets for mutations 
NQO1 and NQO2 share 46% identity in sequence, and are quite similar in their overall 
structure. In fact, the most major structural difference between them is the presence of a 43-
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residue C-terminal tail in NQO1 that is not found in NQO2. In previous work, an NQO2 
chimeric protein containing the C-terminal tail found in NQO1 was created in order to 
determine whether that feature was responsible for the difference in their cofactor preference 
(23). However, this did not yield a significant change in specificity. These findings led us to 
take a site-directed approach to engineer the protein’s specificity by directly comparing the 
active sites of the two proteins. 
A comparison of the active sites of NQO1 and NQO2 revealed that most of the residues 
are similar in their physicochemical properties, with a few exceptions. Through superimposition 
of the two proteins, I identified five different residues within the proteins’ binding sites that are 
significantly different in size and/or charge between the two proteins (Figure 7).   
The first two mutations (Q122G, H72V) were chosen due to their proximity to the 
binding site as well as the difference in size and charge (Figure 7, left panel). Since NADH is a 
larger molecule than NRH, it seemed possible that these residues are involved in steric 
hindrance that interferes with binding of NADH. The third mutation (I128Y) is the closest to 
the binding site of the nicotinamide ring, present on a flexible loop which closes down over the 
active site during binding (19). Its difference in size and aromaticity as well as its proximity to 
the binding site makes it worthy of investigation (Figure 7, middle panel). NADH has an 
additional aromatic ring compared to NRH due to its adenine moiety, and it is possible that the 
tyrosine residue in NQO1 promotes NADH binding through aromatic stacking. The last two 
mutations (E193G and N66Q) were chosen because these two residues participate in a 
hydrogen bond in close proximity to the active site, as seen by the fact that the distance between 
the two heavy atoms is 3.0 Å (Figure 7, right panel).  Since this hydrogen bond is not found in 
NQO1, I hypothesized that these residues may make it more difficult to bind NADH in NQO2 
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due to steric hindrance and reduced flexibility of the protein backbone, shifting specificity to 
NRH which is a smaller molecule.  
 
Figure 7: Target residues for mutagenesis in NQO2 active site chosen through 
superimposition with NQO1. 
NQO2 (magenta carbon atoms) is superimposed with NQO1 (blue carbon atoms), with the five 
residues chosen for mutation labelled. In the right panel, asparagine and glutamic acid in NQO2 
form a hydrogen bond (distance between the two heavy atoms is 3.0 Å) which is not found 
between the respective glutamine and glycine residues in NQO1.  
The final mutant proteins contained multiple mutations in order to determine whether 
they result in a significant difference to the cofactor specificity of NQO2, paving the way for 
future analysis of each residue’s individual contribution. Two mutant species were created, a 
triple mutant dubbed NQO2-trp containing Q122G, H72V, I128Y, and a quintuple mutant 
dubbed NQO2-qtp containing Q122G, H72V, I128Y, E193G and N66Q. 
3.2.2 Site-directed mutagenesis of NQO2 
The desired mutations were introduced to NQO2 using QuikchangeTM site-directed 
mutagenesis protocol. PCR using mutagenic primers was performed in multiple rounds of 
single mutations in order to achieve the final mutant constructs. This ensured the creation of a 
vector library that contained single as well as various combinations of the mutations. The final 
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mutants can be initially analyzed for the mutations’ effect in combination, and the single and 
double mutant vectors created can be used for future residue-by-residue analysis of their 
contribution to the observed effects in cofactor specificity. Since the chosen residues included 
E193 and N66 due to their participation in a hydrogen bond that was not observed in NQO1, 
these sites were deemed most likely to have a pronounced effect on enzyme stability and 
kinetics. Therefore, it was decided that the final products for analysis would be a triple mutant 
(excluding them) and a quintuple mutant (including them), in order to distinguish their effects 
from the rest of the mutations. The PCR product was transformed into E. coli strain XL1B, 
incubated overnight, then the plasmid was isolated and sequenced in order to ensure the 
presence of the desired mutations. The sequencing alignment showed that the triple (Figure B- 
1, appendix B) and quintuple (Figure B- 2, appendix B) mutants (NQO2-trp and NQO2-qtp) 
contained the correct substitutions.   
3.2.3 Expression and purification of NQO1, NQO2 and mutants 
3.2.3.1 Protein purification 
This section describes the purification process and results for wildtype NQO2 in detail, 
as an example for NQO1, NQO2-trp and NQO2-qtp purification where the same protocol was 
used and similar yields were obtained. NQO1, NQO2, NQO2-trp and NQO2-qtp were 
expressed in E. coli strain BL21 as His-tagged constructs in plasmid PProEx-HTa using auto-
induction media (47). The auto-induction media gave a high yield of cells, with an OD600 of 
approximately 10 upon exiting log phase. This corresponds to a cell concentration of 8.0 x 109 
cells/ml. A sample of culture post-incubation showed high amounts of NQO2 expression in 
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SDS-PAGE (Figure 8).  The large amounts of protein expressed contributed to high success of 
the subsequent purification steps, increasing the quality and yield of the final purified proteins. 
 
Figure 8: SDS-PAGE of expression of wildtype NQO2 in E. coli BL21 using auto-
induction media. 
NQO2 is 26 kDa in size. The second lane is a culture sample taken before incubation overnight 
in auto-induction media, representing the uninduced bacteria culture. The 3rd lane is a culture 
sample taken post-overnight incubation, showing the relative amount of NQO2 expressed  
Cells were centrifuged and re-suspended in 50 mM sodium phosphate pH 7.5, lysed 
through French press and purified through nickel affinity chromatography. Each fraction was 
sampled and analyzed with SDS-PAGE (Figure 9). It appears that NQO2 was present in the 
flow-through and washes, suggesting that the column was overloaded with NQO2.  Due to the 
relatively large amounts of expressed protein in the lysate, the purification quality was excellent 
perhaps due to the elimination of most non-specific binding to the column by sheer 
competition. Following nickel-column purification, the eluted protein was digested with TEV-
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protease in the presence of 5 mM DTT. This was performed to cleave the His-tag from the 
protein in order to ensure its normal binding/folding/function during enzymatic assays. 
Digestion with TEV-protease leaves behind two residues at the N-terminus of the protein 
(glycine and alanine) which are not expected to hinder the structure and/or function of the 
protein. His-tag removal was tested by SDS-PAGE before/after digestion, showing that the 
product was approximately 1 kDa smaller (data not shown). The digested protein was dialyzed 
overnight into 50 mM Tris-HCl pH 8 in order to eliminate NaCl and imidazole in preparation 
for anion exchange chromatography. 
 
Figure 9: SDS-PAGE of nickel column purification of NQO2. 
An SDS-PAGE of samples taken through the nickel column purification steps. Lane 2 is the 
flow-through of the lysed cells through the nickel column, lanes 3 through 5 are samples of 
column washes with 50 mM sodium phosphate 500 mM NaCl 20 mM imidazole pH 7. Lanes 6 
and 7 are samples of subsequent elutions with 50 mM sodium phosphate 500 mM NaCl 500 
mM imidazole pH 7.   
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Although purification quality following nickel column was acceptable, additional 
purification steps were performed in order to ensure highest purity for subsequent 
crystallization and enzymatic assays. The protein yield was large enough to allow some loss of 
protein in each step in favor of purification quality. Anion exchange was performed on the 
dialyzed, TEV-protease digested protein, with a NaCl concentration gradient of 0 to 500 mM. 
The protein began eluting at approximately 25 mM NaCl over 13 fractions, each a 
volume of 8 mL. SDS-PAGE of the eluted fractions showed excellent purity (Figure 10).  
 
Figure 10: SDS-PAGE of anion exchange purification of NQO2. 
Anion exchange purification was performed following TEV-protease digestion and dialysis into 
an appropriate buffer. Elution fractions 6-18 at 2 mL/min were yellow in colour, indicating 
presence of NQO2. 
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3.2.3.2 Addition of DTT at the FAD reconstitution step prevents 
dimerization due to disulfide bonds 
The purification protocol for NQO2 requires denaturation and refolding in the presence 
of FAD, in order to fully reconstitute the enzyme with FAD rather than FMN (46). The results 
from the gel exclusion chromatography showed two peaks at the expected elution volume for 
NQO2 rather than one (Figure 11, panel A).  
 
Figure 11: Preparative size-exclusion chromatography of NQO2, with and without 
reducing agent. 
Panel A shows purification with no DTT used, while panel B shows purification with 10 mM 
DTT added into the guanidine-HCl denaturation step. Volume is calculated from the elution of 
void column volume. 
Analysis of peak fractions by reducing SDS-PAGE indicated that both peaks contained 
only NQO2 (Figure 12, panel A). However, non-reducing SDS-PAGE (performed in the 
absence of β-mercaptoethanol) revealed that the fractions corresponding to the first of the two 
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peaks showed bands at both 26 kDa and 52 kDa (Figure 12, panel B). Native NQO2 is 
naturally a dimer, however it does not contain any intermolecular disulfide bonds. Therefore, 
the formation of disulfide bonds between two monomers is inappropriate for purification of 
functional NQO2, and mis-folding may have occurred when the protein re-folded on the 
column.  
              
Figure 12: SDS-PAGE analysis of size-exclusion chromatography purification of NQO2. 
In Panel A, the fractions were run on a reducing SDS-PAGE, while panel B is a non-reducing 
gel. The first four fractions following the ladder in both gels correspond to the first of the two 
NQO2 peaks seen on the chromatograph, while the last four correspond to the second, bigger 
peak.  
This may not be resolved by the addition of reducing agent after refolding, so the 
protein eluted in the first peak was discarded and only the fractions from the second peak were 
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pooled and concentrated for later analysis. When the purification was repeated, 10 mM DTT 
was added into the guanidine-HCl denaturation step. The results from the size-exclusion 
chromatography from the second purification attempt showed only one peak (Figure 11, panel 
B) which was confirmed to be NQO2 by SDS-PAGE (not shown). The protein from the second 
purification was successfully used for analysis and crystallography. The addition of DTT was 
included in the purification process for NQO1, NQO2-trp and NQO2-qtp as well. An SDS-
PAGE of the final products from each protein’s purification shows that they are of acceptable 
purity for usage in enzymatic assays and crystallography (Figure 13). The total yield of 
purified protein was an average of 60 mg per litre of culture. 
 
Figure 13: Purified NQO1, wildtype NQO2, NQO2-trp and NQO2-qtp. 
An SDS-PAGE of the products of protein purification of NQO1, wildtype NQO2, NQO2-trp 
and NQO2-qtp.  
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3.2.4  CD scans of NQO1, NQO2 and mutants 
  Circular dichroism scans were conducted on NQO1, NQO2, NQO2-trp and NQO2-qtp 
(Figure 14). This was performed to observe any effects the mutations may have had on the 
general structure of NQO2, especially since a denaturation/refolding step was involved in the 
purification protocol. It also served to determine if the mutations changed the physical 
properties of NQO2 to approach those of NQO1.  The data obtained showed ellipticity signal 
minima at 222 nm for all four proteins, as well as signal maxima at 195 nm, indicating 
significant helical content in the proteins. The highest to lowest maxima (195 nm) were NQO2-
qtp, wildtype NQO2, NQO2-trp and NQO1. The highest to lowest minima (222 nm) were 
NQO1, wildtype NQO2, NQO2-trp and NQO2-qtp. The scans for all four proteins had the same 
general curve shape, any observable differences were in the amplitude of signal.  
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Figure 14: Circular dichroism scans of NQO1, NQO2, NQO2-trp and NQO2-qtp. 
CD scans of the four proteins at 0.5 mg/mL in a 0.1 mm cuvette, ranging from 190 to 260 nm. 
All values were converted to mean residue ellipticity (ϴMRE) which normalizes for 
concentration and size of the proteins. 
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Generally speaking, the CD scans of the mutants were within the same signal range and 
curve shape of the proteins, implying that the mutations did not significantly change the 
secondary structure of the protein. As for the specific differences in signal amplitude, there is a 
trend in the intensity of signal across NQO1 and the mutants. For example, the quintuple 
mutant possesses both the strongest maxima and minima, while NQO1 possesses the weakest 
strength signal. Across the two mutants and NQO1, the differences in signal intensity at the 
maxima and minima stays consistent.  This implies that the only difference between these three 
proteins scans is signal strength. This observation can be explained by a margin of error in 
protein concentration, since a higher concentration of protein correlates to larger signal and vice 
versa. Overall, these spectra indicate that all the proteins are well folded. 
3.2.5 Thermal denaturation curves of NQO1, NQO2 and mutants 
Thermal denaturation curves were measured for NQO1, wildtype NQO2, NQO2-trp and 
NQO2-qtp using circular dichroism (Figure 15) in order to determine if the mutations had an 
effect on the thermostability of NQO2. The melting temperature (Tm) calculated from these 
curves for NQO1, wildtype NQO2, NQO2-trp and NQO2-qtp were 54.10, 75.05, 71.68 and 
64.24 °C respectively. The most thermostable protein is wildtype NQO2, followed by NQO2-
trp, NQO2-qtp and NQO1. The melting curves have sigmoidal shape indicating co-operative 
unfolding of the protein subunits. The results show that NQO1 is significantly less stable than 
NQO2. The triple and quintuple mutant were less stable than NQO2, getting closer to the 
melting temperature to that of NQO1. 
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Figure 15: Thermal denaturation curves measured using circular dichroism for NQO1, 
wildtype NQO2, NQO2-trp and NQO2-qtp. 
The temperature was increased from 20 to 90° C, and the signal was measured at 220 nm. All 
values were converted to mean residue ellipticity (ϴMRE) which normalizes for concentration 
and size of the proteins 
3.2.6 Enzyme kinetics measuring the effect of the mutations on NADH-
driven mechanism 
Following the purification of the mutants, enzyme kinetic assays were conducted as key 
experiments for this project, to determine if the protein’s catalytic rates while utilizing NADH 
were affected by the mutations. I have performed these experiments on the four proteins 
(NQO1, NQO2, NQO2-trp and NQO2-qtp) using NADH, and paved the way for future kinetic 
analysis using NRH. The dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) was used as an indicator of enzyme activity as in previous methods with NQO1 and 
NQO2 (2, 17, 46, 53, 54). The assay combines a constant amount of protein, menadione and 
MTT alongside variable amounts of NADH into the buffer to obtain the catalytic rates of 
reaction. The protein utilizes NADH to reduce the quinone substrate (menadione) which 
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subsequently reduces the MTT dye in a non-catalyzed reaction. Upon reduction, the absorbance 
of MTT changes drastically which can be measured at 610 nm with an extinction coefficient of 
11.3 x 103 M-1 cm-1. The rate of change in absorbance is used to calculate the rate the enzyme is 
turning over substrate at that particular concentration of NADH, which can be used to obtain 
the catalytic efficiency of that protein as well as a Michaelis-Menten curve.  
Since menadione can act as a substrate inhibitor of NQO2 at higher concentrations, the 
assay uses 10 µM menadione which was reported to be a low enough concentration that does 
not result in significant substrate inhibition (55). Both NQO1 and NQO2 can reduce 
menadione, therefore the reagents in the assay were consistent across the four proteins. The 
only variable between each protein’s kinetic assay was the concentration of protein needed for a 
proper steady-state measurement. Keeping as many factors as possible consistent improves the 
reliability of the results when comparing the activities of the four proteins. 
3.2.6.1 Kinetics of wildtype NQO1 using NADH as a cofactor 
This assay was performed in order to ensure that the results were comparable to 
previously measured NQO1 Km of 70 µM and kcat of 515 s-1 (30,900 min-1) using NADH as a 
cofactor (Table 1). Since the overall goal is to increase the catalytic rates of NQO2 with NADH 
to the rates seen from NQO1, the kinetic parameters obtained from this assay serve as a good 
baseline for comparison to the wildtype and mutant catalytic rates with NADH. The enzymatic 
rate of NQO1 using NADH as a cofactor and menadione as a substrate was measured using an 
MTT-dependent assay (Figure 16).  The assay was performed in triplicate and the data were 
fitted to Michaelis-Menten kinetics equation using GraphPad Prism 4. Since this assay was 
performed to obtain relative kinetic parameters with NADH without determining the effect of 
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the two substrates individually, the reported parameters are apparent constants. The data fitting 
reported a Km(app) of 291 µM with a 95% confidence interval of 191 to 389 µM, and a kcat(app) of 
240 s-1 with a 95% confidence interval of 213 to 265 s-1. The kcat and Km values obtained from 
this experiment had a 2-fold and 4-fold difference, respectively, from the literature values. It is 
worth noting that the previously quoted kcat and Km used a different assay to measure these 
values, with DCIP as an indicator rather than MTT. While that may account for some of the 
difference in the values obtained, the margin of error is not expected to be significant enough to 
question the reliability of the data when comparing to the kinetic parameters observed for 
wildtype NQO2 and the mutants. Since the values obtained for NQO1 are close to the literature 
values and were performed under the same assay conditions as wildtype NQO2 and the 
mutants, they provide a reliable basis for comparison and interpretation of the data. 
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Figure 16: Enzymatic rate of NQO1 against NADH concentration. 
The concentrations of MTT and menadione were kept constant while the concentration of 
NADH was increased, and an increase in absorbance signifies MTT reduction. Performed in 
triplicate. 
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3.2.6.2 Kinetics of wildtype NQO2 using NADH as a cofactor 
This assay was performed in order to ensure that the results were comparable to 
previously measured NQO2 Km of 330 µM and kcat of 35 min-1 using NADH as a cofactor 
(Table 1). The enzymatic rate of NQO2 using NADH as a cofactor and menadione as a 
substrate was measured using the same MTT-dependent assay as in section 3.2.6.1 (Figure 17).  
By fitting the data to the Michaelis-Menten equation, the data reports a  Km(app) of 1088 µM 
with a 95% confidence interval of 645 to 1530 µM, and a kcat(app) of 3.76 min-1 with a 95% 
confidence interval of 3.28 to 4.25 min-1. The kcat and Km obtained from this experiment are 
within an order of magnitude from the aforementioned values published in literature, although 
they were further from the literature values than the parameters obtained using NQO1. As 
expected, the catalytic rates with respect to NADH are much higher in NQO1 than NQO2, since 
it is the native substrate of NQO1.  
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Figure 17: Enzymatic rate of wildtype NQO2 against NADH concentration. 
The concentrations of MTT and menadione were kept constant while the concentration of 
NADH was increased. Performed in triplicate. 
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3.2.6.3 Kinetic analysis of wildtype NQO2 versus both mutants using 
NADH as a cofactor 
In order to observe the effect the mutations had on the enzyme kinetics of NQO2, the 
same MTT-dependent assay that was performed on wildtype NQO2 was also performed on 
NQO2-trp and NQO2-qtp using NADH as a cofactor (Figure 18). The data from the above 
curve obtained for wildtype NQO2 is also included in the figure for comparison (shown in red 
data points). The full Michaelis-Menten curve for the enzymes could not be obtained due to the 
fact that there was no saturation observed for the mutants at very high concentrations of NADH. 
Although the wildtype enzymatic rates reached plateau by approximately 3 mM of NADH, the 
same assay with the mutants did not show saturation up to 10 mM. Attempting to raise the 
concentrations of NADH higher than 10 mM was not feasible due to highly rapid exhaustion of 
reagents available. It is important to mention that control tests were performed to ensure that 
there was no background reduction of the dye by individually eliminating each of the protein, 
menadione and NADH when running the assay. This determines if there was any direct 
reduction of the dye that resulted in background signal that could be mistaken for enzyme 
activity. There was no observable reduction of the dye when any of the protein, NADH, or 
menadione were not included in the assay (data not shown). 
The fact that saturation with the mutants was not observed up to 10 mM of NADH was 
unexpected, considering that the mutants are shown to have higher enzymatic rates using 
NADH compared to the wildtype. This implies that the mutations may have had a mixed effect 
on the protein’s catalytic properties by significantly both the Km(app) and kcat(app). Since 
saturation was not observed for the mutants, fitting to the Michaelis-Menten equation would not 
be reasonable due to very large uncertainties. 
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Figure 18: Enzymatic essay comparing the kinetics of wildtype NQO2, NQO2-trp and 
NQO2-qtp using NADH. 
Very high concentrations of NADH (up to 10,000 µM) were used in an attempt to realize the 
full saturation curve for the mutants. The saturation curve obtained for wildtype NQO2 is 
included for comparison (red data points). Assay for both mutants was not performed in 
triplicate due to the amount of reagents and enzyme exhausted at high NADH concentrations. 
The three data curves are shown separately in the right column of panels to visualize each trend 
of data. 
Since it was not possible to obtain the full Michaelis-Menten curve for the enzymes, the 
catalytic efficiency at lower concentrations of NADH was used to compare the effect of the 
mutants on the cofactor specificity of NQO2 (Figure 19). The catalytic efficiency is defined by 
kcat/Km, and it can obtained by calculating the slope of the enzymatic rate at low concentrations 
of NADH – low enough that it is still linear without any saturation taking place. As seen in 
Equation 2, when the substrate concentration [S] is much lower than the Km, the Michaelis-
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Menten equation can be rewritten to estimate enzymatic rates as a liner function of substrate 
concentration [S] with a slope of total enzyme concentration [E]t  multiplied by kcat/Km. Vmax is 
the maximal rate of reaction, which equals the turnover number kcat multiplied by [E]t .The 
catalytic efficiency (kcat/Km) is a measure of how efficiently the protein can turn over substrate, 
expressed in concentration of substrate over time. The higher the catalytic efficiency, the better 
the enzyme turns over substrate.  
Equation 2: Linear estimation of enzymatic rates at low substrate concentrations 
𝑅𝑎𝑡𝑒 = 𝑉𝑚𝑎𝑥 ∙
[𝑆]
𝐾𝑚 + [𝑆]
    
𝑤ℎ𝑒𝑛  [𝑆] ≪ 𝐾𝑚 , 𝑅𝑎𝑡𝑒 ≈ [𝐸]𝑡 ∙
𝑘𝑐𝑎𝑡
𝐾𝑚
⁄ ∙ [𝑆] 
The most important information needed from these kinetics experiments is a comparison 
of the effects of the mutations on the catalytic rates of the enzyme, therefore comparing the 
catalytic efficiencies of the proteins is a suitable analysis for the purpose of this project. The 
data were fit to a linear equation, and the catalytic efficiencies for the wildtype NQO2, NQO2-
trp and NQO2-qtp were 13, 110 and 918 M-1 s-1. The NQO2 quintuple mutant had a catalytic 
efficiency over 70-fold bigger than wildtype NQO2, which is an exciting result showing that 
the mutations have significantly improved the efficiency of the enzyme using NADH. The 
catalytic efficiency obtained for wildtype NQO2 through this method can be compared to the 
efficiency calculated through the kinetic parameters obtained from the full curve, since those 
were achievable for the wildtype (Figure 17). Dividing the kcat(app) by the Km(app) from the 
Michaelis-Menten curve fit yields a catalytic efficiency of 57.66 M-1s-1, which is within a 5-fold 
difference from 13 M-1 s-1 that was calculated by the linear approximation method (Figure 19). 
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Considering the previously listed confidence interval of the parameters obtained from the 
Michaelis-Menten curve, the values are sufficiently close to each other to validate the linear 
approximation method of calculating the catalytic efficiency.  
 
MTT-dependent enzyme kinetics assay comparing the catalytic efficiency of NQO2 versus 
NQO2-trp and NQO2-qtp, using NADH as the cofactor and menadione as the substrate. 
Performed in triplicate. 
 The enzymatic assays revealed the exciting fact that substituting these residues had a 
pronounced effect on the cofactor specificity of NQO2 with NADH. The mutants, especially 
NQO2-qtp, had significantly higher catalytic efficiency with NADH compared to the wildtype. 
Figure 19: Enzyme kinetics comparing catalytic efficiency of wildtype NQO2, NQO2-trp 
and NQO2-qtp using NADH 
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This opens the door for performing the same kinetic analysis using NADPH and NRH. Most 
importantly, although there is still plenty of room for improvement and fine tuning of the 
mutant, the results are quite promising of an NQO2 that can be used in vivo to characterize the 
physiological role of the enzyme. 
3.3 In silico and crystallography structural analysis of 
NQO2 and NQO1 
In order to examine how NQO2 binds NRH, a structural comparison to other 
flavoenzymes which utilize NADH (including NQO1) has been quite informative. The initial 
reasoning for performing this comparison was to infer any potential shared binding site 
attributes amongst NQO1 and the other flavoenzymes that are responsible for their preference 
towards NADH, therefore helping illuminate what needs to be changed to make NQO2 specific 
to NADH. However, the structural comparison revealed that NQO2 and NQO1 have different 
binding stereochemistry altogether. An attempt at co-crystallization of NQO2 with NADH 
yielded discernible electron density for the nicotinamide moiety, which was useful for 
understanding how nicotinamide stacks onto the FAD molecule within the active site. 
3.3.1 In silico comparison of NQO2 and NQO1 active site compared to 
related flavoenzymes 
The electron transfer mechanism commonly used by NADH-utilizing flavoenzymes 
requires that the nicotinamide ring stacks onto the isoalloxazine ring of FAD, bringing the two 
reducing sites from each molecule in close proximity for the electron transfer to occur. Indeed, 
the majority of the enzyme structures which include both NAD and FAD from the Protein Data 
Bank (PDB) showed the two ring structures stacking together as such. PDB ID structures 1F3P, 
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1GEU, 2EQ7, 2NPX, 2RAB, 3CGD, 2YVG, 3GD4, and 4EMI (56–63) (Table 4) have been 
superimposed by the isoalloxazine ring in order to compare how these proteins bind their 
respective NAD molecules (Figure 20).  The NAD molecules from these proteins bind at the 
re-face of the isoalloxazine ring. Panel B adds the FAD molecules from NQO1 (yellow) and 
NQO2 (orange) as well as the two proteins’ backbone structures. In NQO1 and NQO2, the re-
face is buried within the protein, as seen in Panel B by the interference of a backbone loop from 
both structures. In addition, the tail of the FAD molecule is projecting towards a different angle 
in NQO1 and NQO2 in comparison with the FAD from the other protein structures. The fact 
that the re-face is buried in NQO1 and NQO2 means that it is impossible to bind NADH at the 
re-face as observed in all other flavoenzyme structures. 
Table 4: List of proteins in the in silico superimposition with NQO2 and NQO1 
1F3P Ferrodoxin reductase 
1GEU Glutathione reductase 
2NPX NADH peroxidase 
2RAB Glutathione amide reductase 
3CGD CoA-disulfide reductase 
2YVG Ferrodoxin reductase (blue-semiquinone) 
3GD4 Murin apoptosis-inducing factor 
2EQ7 Lipoamide dehydrogynase 
4EMI Toluene dioxygenase reductase 
 
49 
 
 
Figure 20: Steric interference of NQO2 and NQO1 backbone with consensus nicotinamide 
stacking position from other relevant protein structures 
Panel A shows the FAD molecules (magenta carbons) and NAD molecules (blue carbons) 
stacking from protein structures 1F3P, 1GEU, 2NPX, 2EQ7, 2RAB, 3CGD, 2YVG, 3GD4, and 
4EMI. All proteins were superimposed by the isoalloxazine ring of the FAD molecule. Panel B 
adds the FAD and backbones of NQO1 (yellow) and NQO2 (orange), superimposed onto the 
other structures by the isoalloxazine ring of the FAD molecule. The re-face and si-face of FAD 
are indicated, with the re-face facing upwards. 
3.3.2 Crystallization of NQO2 with NADH soak 
Part of the mystery surrounding the cofactor specificity of NQO2 was whether or not it 
has the ability to bind and utilize NADH. NRH is known as the primary cofactor for NQO2 but 
previous work reported a weak Km of approximately 330 µM using NADH (Table 1). This, 
alongside the kinetic analysis from this project, supports that NQO2 can indeed bind and utilize 
NADH. This led to attempting crystallization of NQO2 with NADH. Our hypothesis was that 
NQO2 may be binding NADH and staying in the bound state for a prolonged period, making 
substrate turnover inefficient. If this were the case, obtaining a crystal structure of that 
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intermediate stage would be feasible. Therefore, NQO2 crystals were soaked in a cryoprotectant 
solution containing 10 mM NADH. Upon soaking, the crystals were observed to turn from 
yellow to colourless, and stayed colourless for a minimum of 5 minutes. This may imply that 
NQO2 is being reduced and staying reduced for that duration. The soaked crystals were 
immediately frozen and mounted for data collection. The full crystal structure was visualized in 
PyMOL (Figure 21). The RMSD of the crystal structure backbone compared with NQO2 
structure 1QR2 is 0.207 Å, which implies almost identical backbone structure. 
 
Figure 21: Full crystal structure obtained from crystallization of NQO2 with NADH soak 
and refinement with nicotinamide 
Cartoon-representation of NQO2 in magenta with the FAD molecules shown with yellow 
carbons, and the refined nicotinamide in blue. The structure was refined using PHENIX with 
nicotinamide in the active site. 
Electron density within the binding site was observed, which was smaller than an 
NADH molecule and about the size of the nicotinamide moiety (Figure 22). Upon refinement 
with nicotinamide, it became apparent that this electron density was a good match. Data and 
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refinement statistics can be found in Table 5. There was no density observed resembling the 
rest of the NADH molecule. This could mean that either the rest of the NADH molecule adopts 
a more erratic and less consensus sequence leading to poor electron density, or it could be 
indicating that the molecule has degraded where only the nicotinamide moiety is present in the 
active site. Three hydrogen bonds are present between the refined nicotinamide moiety, N161 
from NQO2, and a water molecule in the active site (Figure 23). The presence of hydrogen 
bonds was determined by a bond length of 3.0 Å or less between the participating molecules. 
These interactions support that the refined nicotinamide molecule is situated in an optimal 
binding position within the enzyme active site, and accurately represents how the nicotinamide 
moiety stacks onto the FAD in NQO2. 
 
Figure 22: Electron density from NQO2 crystal soak in 50 mM NADH 
Electron density from the Fo-Fc observed above the isoalloxazine ring within the binding site of 
NQO2 after soak in cryoprotectant containing 50 mM NADH. Nicotinamide was refined within 
this structure using PHENIX. Residues in close proximity are labelled with 1-letter 
abbreviations. 
N161 W105 
G174 
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Figure 23: Hydrogen bonding of refined nicotinamide moiety with N161 and water in 
NQO2 active site. 
Hydrogen bonds between the refined nicotinamide moiety (green carbons), N161 and water 
molecule in the NQO2 active site. The co-enzyme FAD is shown with yellow carbons. Taken 
from the crystal structure obtained from co-crystallization of NQO2 with NADH. Bond 
distance shown in Angstroms. Bond lengths measured and illustrated in PyMOL (64). 
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Table 5: Crystallographic data collection and refinement statistics 
Crystal NQO2-NADH 
Ligand NADH 
Wavelength (Å) 1.5481 
Space Group P212121 
Unit Cell Dimensions (Å) 56.19, 83.35, 106.37 
Resolution (Å) 17.1 – 2.2 
aRsym 0.113 (0.471) 
aI/σ(I) 14.4 (4.8) 
Completeness 99.7 (100.0) 
Multiplicity 7.1 (7.0) 
Unique Reflections 25988 
Rwork/Rfree 0.1673/0.2009 
Ramachandran Plotb (%) 
Most Favoured 
Generously Allowed 
Disallowed 
 
95.6 
3.3 
1.1 
RMS Deviations 
Bond Lengths (Å) 
Bond Angles (deg) 
 
0.008 
1.114 
Mean A.D.P. values (Å2) 
Protein 
Solvent 
 
27.9 
30.0 
aValues in parentheses refer to the highest resolution shell. 
  bRamachandran plot statistics were calculated using CCP4 
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4 Chapter 4 – Discussion 
 
4.1 Summary of findings 
The results of this project can be summarized into two major categories: the effects of the 
site-directed mutagenesis on the properties of NQO2 and its catalytic rates utilizing NADH; and 
a structural-based analysis that includes the in silico comparison of NQO2 to NQO1 and other 
flavoenzymes as well as co-crystallization of NQO2 with NADH.  
After mutating the chosen residues within the active site of NQO2 to those corresponding 
residues found in NQO1, the enzyme kinetics assays showed that the mutations increased the 
specificity of NQO2 towards NADH. The triple mutant and the quintuple mutant had a high 
catalytic efficiency using NADH, with the quintuple mutant’s effect being most significant at 
70-fold higher compared to wildtype NQO2. This was a very exciting result as it signifies that 
the mutated residues play an important role in the cofactor specificity of NQO2. Interestingly, 
attempting to obtain the full saturation curve for the wildtype and mutants was not possible at 
feasible concentrations of NADH (up to 10,000 µM), a phenomenon only occurring with the 
mutants and not the wildtype. This suggests that the Km(app) and kcat(app) of the mutants are 
extremely high, which invites some speculation as to why this phenomenon was observed. 
In order to determine whether the mutations had an effect on the physicochemical properties 
of NQO2, thermal denaturation curves were obtained for the triple and quintuple mutant as well 
as wildtype NQO2 and NQO1. The triple and quintuple mutant had lower melting temperatures 
compared to wildtype NQO2, bringing them closer to the lowest melting temperature of NQO1. 
55 
 
These results imply that mutating these residues has shifted the stability of NQO2 closer to that 
of NQO1, which is not surprising considering that the residues substituted were the ones found 
in NQO1, and a hydrogen bond was removed in the process. This paves the way for future 
experiments analyzing the contribution of each of the individual residues to the thermal stability 
of NQO2.  
The in silico comparison of NQO2 and NQO1 superimposed with other flavoenzymes that 
utilize NADH revealed that NQO1 and NQO2 bind their respective nicotinamide cofactor on 
the opposite face of the isoalloxazine ring of FAD, compared to other NADH-utilizing 
flavoenzymes. Considering that NQO2 and NQO1 have yet to be successfully co-crystallized 
with their respective cofactors (NRH and NAD(P)H), their differing stereochemistry may shed 
some light on why that task has proven more difficult than the other  flavoenzymes. It also 
reinforces the importance of uncovering their binding specifics as it would reveal a new binding 
mode of nicotinamide cofactors onto the FAD co-enzyme.  
An attempt at crystallization of NQO2 with NADH had rather interesting implications 
despite not being able to show the full electron density for NADH, and only that of the 
nicotinamide moiety. This observation suggests two different possibilities: the rest of the 
NADH molecule does not bind in a consensus binding position and is therefore unable to be 
visualized through crystallography, or that breakdown of the NADH molecule at the N-
glycosidic bond has led to only nicotinamide being present in the binding site. This opens the 
door for future crystallization experiments to determine whether the full molecule was actually 
present in the binding site or if the molecule had degraded. 
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The results from this project illuminated some new facets to cofactor binding within NQO2. 
It opens the door for further examining the factors that influence the binding preference of 
NQO2, paving the way for future investigation and full characterization. 
4.2 Structure and binding 
Attempting to co-crystallize NQO2 with NADH yielded a discernible electron density for 
the nicotinamide moiety within the binding site, but no density resembling the rest of the 
NADH molecule (Figure 22). Observing the nicotinamide stacked upon the isoalloxazine of 
FAD supports that the mechanism of electron transfer from nicotinamide to FAD takes place as 
expected in NQO2. Although it is generally assumed that stacking of the N4 in nicotinamide 
upon N10 in FAD is how electron transfer occurs between a nicotinamide-based donor and the 
FAD in a flavoenzyme, it is helpful to observe this in NQO2 since it was seen in the in silico 
superimposition that NQO1 and NQO2 have a different mode of cofactor binding than other 
NADH utilizing flavoenzymes (Figure 20).  
Since we have observed that the NQO2 crystals seem to remain in a reduced state for a 
prolonged period upon soaking in NADH (indicated by a change of colour in the crystals from 
yellow to colourless, and remaining colourless for over 5 minutes) this may be due to the 
NADH staying within the NQO2 active site for an extended period. It is unclear whether the 
reason NQO2 cannot efficiently use NADH is due to a low rate of electron transfer to FAD 
(e.g. due to non-optimal binding) or if it is due to a low release rate of NADH from the active 
site None of the results obtained in this project have contradicted the hypothesis that NQO2 
cannot utilize NADH efficiently due to prolonged binding of the cofactor, rendering it overall 
inefficient. Therefore, it is plausible that this is the answer to the question of what determines 
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the cofactor preference of NQO2 for NRH over NADH.  However, it is also possible that this 
observation is caused by exchange of oxidized NAD with NADH in solution, refreshing the 
reduced state of the protein until the NADH in the soaking solution is depleted. In order to 
examine whether this phenomenon is truly due to extended binding of NADH within the active 
site of NQO2, future assays on the binding kinetics of NQO2 must be pursued. 
The fact that we did not observe the rest of the NADH molecule in the structure from the 
co-crystallization experiment suggests two possibilities: One being that the rest of the NADH 
molecule bound within NQO2 does not assume a consensus binding position, since 3D mapping 
through crystallography relies on ordered structure throughout the unit cell in the crystal. If the 
rest of the NADH molecule binds (or floats freely) in a disordered fashion within NQO2, it 
would be highly difficult to visualize it in the crystal structure. The second possibility is that 
mass breakdown occurred in the NADH molecule at the N-glycosidic bond connecting the 
nicotinamide to the ribose (and subsequently the rest of the NADH molecule). N-glycosidic 
bonds are known to be highly prone to hydrolysis in even slightly acidic environments. The 
NADH soaking/cryoprotectant solution used in this experiment was buffered at 7.5 pH which 
was expected to be an appropriate pH for the protein and NADH. However, repeating the 
experiment at pH 8 or 8.5 (at which NQO2 remains stable) may be worthwhile to determine 
whether the rest of the NADH molecule can be seen in the binding site. We do not expect the 
NADH purchased and used to contain high levels of free nicotinamide, however that could be 
another possible source for the lone nicotinamide moiety discerned in the binding site. 
Since hydrogen bonding was observed between the refined nicotinamide molecule with 
N161 and water in the active site, this supports that the refined nicotinamide is in an optimal 
position for protein binding (Figure 23). Therefore, it is reasonable to assume that this structure 
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accurately represents the binding of nicotinamide derivatives in the NQO2 active site. Based on 
that assumption, an NADH molecule from the superimposition of the NADH-utilizing 
flavoenzymes was modelled into the NQO2 crystal structure obtained from the co-
crystallization experiment, guided by the position of the refined nicotinamide moiety (Figure 
24). Since the NADH molecules in the flavoenzyme superimposition were all shown to adopt a 
very similar extended conformation, any of them were considered representative of the 
conformation NADH prefers to adopt during protein binding (Figure 20). The nicotinamide 
moiety of the modelled NADH molecule was superimposed onto the refined nicotinamide 
within the NQO2 structure using PyMOL, and the nicotinamide-ribose bond was manually 
rotated to allow for better fit within the binding cavity (Figure 24, panel A). The manual 
adjustments needed to observe a plausible fit were minor; the original and rotated NADH are 
shown superimposed by their nicotinamide moieties for the sake of comparison (Figure 24, 
panel B). For better clarity on where the residues chosen for mutation lie in this proposed 
model, the five residues are highlighted and labelled (Figure 24, panel C). I propose this model 
as an estimation of NADH binding within the NQO2 active site, informed by the position of the 
nicotinamide that was observed in the co-crystallization experiment. The fact that minor 
adjustments were required to the extended conformation NADH seen in the other flavoenzyme 
structures makes this model promising of what occurs in the enzyme. The five residues chosen 
for mutation lie in close proximity to the adenosine diphosphate portion of NADH, which is 
where NADH differs from the native substrate for NQO2, NRH. It is plausible that these 
residues are interacting with that portion of NADH, and influencing its binding and dissociation 
rates within NQO2. Although it is unclear how these residues may be involved in the preference 
of NQO2 for NRH over NADH, this attempt at modelling NADH deems it unsurprising that 
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mutating these residues had a pronounced effect on the catalytic rates of NQO2 with NADH. It 
is possible that these residues provide favorable interactions with NADH, which increases its 
dissociation rate within NQO2 and hinders the turnover efficiency of the enzyme. This logic is 
in line with the effects on catalytic efficiencies observed from substituting these residues in the 
mutant proteins. 
 
Figure 24: Representative NADH modelled into NQO2 structure obtained from co-
crystallization with NADH 
A representative NADH molecule taken from previously obtained NADH-bound flavoenzyme 
structure was modelled into the NQO2 crystal structure refined with nicotinamide. The 
nicotinamide moiety of NADH was superimposed onto the refined nicotinamide, and 
nicotinamide was omitted for clarity. The ribose-nicotinamide bond in NADH was manually 
rotated using PyMOL for a better fit in the nicotinamide cavity, as shown in Panel A (NADH 
with blue carbons, FAD co-enzyme shown in yellow carbons). Panel B shows a comparison of 
the original NADH molecule and the rotated NADH, superimposed by the nicotinamide moiety. 
Panel C shows the same modelled NADH within the NQO2 binding site as in Panel A, but with 
the five residues chosen for mutation highlighted in magenta and individually labelled. 
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4.3 Mutations and their effect on NQO2 
4.3.1 Physicochemical changes caused by the mutations 
 Upon creating and purifying the NQO2 mutants, CD scans and denaturation curves were 
obtained in order to determine if the mutations had significantly changed the physicochemical 
properties of NQO2. Since one of the goals of using site-directed mutagenesis was to avoid 
making any major changes to the shape of the protein, ideally we wanted to see relatively little 
change in the properties of NQO2. If there were changes in physicochemical properties, we 
expected that they approximate those of NQO1 when compared to wildtype NQO2. Generally 
speaking, the CD scans of the mutants as well as the wildtype NQO2 and NQO1 had the same 
curve shape; a sign that there were no significant changes to the secondary structure of the 
protein (Figure 14). The shape of the curves was as expected of a predominantly helical 
protein. 
As for the specific differences in signal amplitude, there was a trend in the intensity of 
signal across NQO1 and the mutants. For example, the quintuple mutant possesses both the 
strongest maxima and minima in terms of signal, while NQO1 possesses the weakest strength 
signal. Across the two mutants and NQO1, the differences in signal intensity at the maxima and 
minima stays consistent.  This implies that the only difference between these three proteins’ 
scans is signal strength. This observation can be explained by a margin of error in protein 
concentration, since a higher concentration of protein correlates to larger signal. Although stock 
solutions of the proteins were carefully measured by Bradford assay in triplicate, it is possible 
that some margin of error was introduced when diluting the proteins to the same concentration. 
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This may also explain why NQO1 has weaker signal strength that that of wildtype NQO2, since 
it is expected that their similar helical content would result in similar 195 and 220 nm signal.   
  On the contrary, the wildtype NQO2 somewhat disrupts this trend by having a 
relatively strong signal at 195 nm that is very close to that of the quintuple mutant, but its signal 
at 220 nm is weaker and approaches that of NQO1. This inconsistency in signal strength may 
imply a difference in secondary structure rather than a concentration margin of error. However, 
while observing the specifics of these CD curves it is important to note that the 0.1 mm cuvette 
used in order to be able to discern a signal in the lower wavelength range will result in a weak 
overall signal that is susceptible to noise. Therefore it is best to use it as a qualitative analysis, 
as the signal noise may be responsible for the inconsistency in the curve belonging to NQO2. 
After all, the conversion of the raw data to mean residue ellipticity (ϴMRE) will amplify 
experimental error. Therefore, it is reasonable to assume that the CD scans show that the 
mutants did not have any major structural effects to the protein, and the small discrepancies 
present can be accounted within margin of error.  
The thermal denaturation assay on the four proteins revealed the mutations had a 
significant effect on the thermostability of NQO2. NQO2 had the highest melting temperature, 
followed by the triple mutant, quintuple mutant and NQO1 in decreasing order. The results 
show that the five mutations have contributed significantly to lowering the stability of NQO2, 
approximating that of NQO1. This is an unsurprising observation, since the residues substituted 
were those found in NQO1. Additionally, the E193G and N66Q mutations (included only in the 
quintuple mutant) result in the removal of a hydrogen bond, therefore lowering the 
thermostability of the folded state. 
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Previous literature reports melting temperature of 70 °C for NQO2 in HEPES-OH 
buffer (53). As for NQO1, the literature reports a melting temperature of 54.0 °C in sodium 
phosphate buffer, and two examples in HEPES-OH buffer reporting values of 56.0 and 55.7 °C 
(65, 66). The melting temperature of 54.1 °C obtained for NQO1 is very close to the literature 
values, especially the ones performed in the same buffer (sodium phosphate). However, the 
melting temperature obtained for wildtype NQO2 was higher than the literature value, 75.05 °C 
compared to 70 °C respectively. Comparing the melting temperatures of NQO1 and NQO2 
from these results to the values found in literature, NQO1 was within 1 degree which is within 
an acceptable range to show the assay worked as expected. On the other hand, NQO2 had a 
melting temperature 5 degrees higher than that found in the literature value. It is important to 
note that the assay used to obtain the literature value for NQO2 included 1% w/v DMSO which 
was not used in this project. This may account for the discrepancy of the values between the 
observed Tm and the literature. The aforementioned reported values for NQO2 used a HEPES-
OH buffer, pH 7.5 buffer compared to the 20 mM sodium phosphate, 100 mM NaCl, pH 7.5 
used in this assay. Although both of those buffers are not expected to have an effect on 
thermostability, it can be seen from the literature values of NQO1 that the melting temperature 
observed in HEPES-OH buffer are different by up to 1.7 °C than in sodium phosphate. 
Repeating these experiments with the same buffer as the literature values is suggested in order 
to determine whether the difference in values for NQO2 is due to the assay conditions. Since all 
four proteins were subjected to the same assay, ultimately the assay compared the 
thermostability of the mutants to the wildtype proteins, and showed the effects of the mutations. 
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4.3.2 Kinetics of the mutants compared to wildtype NQO2 and NQO1 
 The kinetics experiments were the core of this project and they resulted in rather 
interesting observations. The most important is that the mutations increased the catalytic 
efficiency of the enzyme with NADH significantly, especially in the quintuple mutant 
(Figure 19). Since the quintuple mutant showed a 70-fold increase in catalytic efficiency 
(kcat/Km) compared to the wildtype, and a 9-fold increase compared to the triple mutant, it 
appears that the last two mutations (E193G, N66Q) had the most significant effect on 
increasing NADH turnover. These two residues form a hydrogen bond in NQO2 that is not 
present in NQO1, and they can be visualized as a “bridge” in proximity of the active site of 
NQO2 (Figure 2). These two residues seem to make the general area of the binding site of 
NQO2 more restricted than that of NQO1, therefore it is reasonable to suggest that they had 
the biggest effect on how the tail portion of NADH binds. The tail portion in this case refers 
to the part of NADH which differs from NRH, the adenosine diphosphate moiety (Figure 
4). Another option to consider is that the dramatic increase in catalytic efficiency for the 
quintuple mutant could be due to synergistic effects by bringing all five mutations together, 
and not solely due to the N66Q, E193G mutations. It seems that the residues chosen for 
mutation play a large role in the preference of NQO2 for NADH, perhaps by sterically 
interfering with how NADH would normally lie within the binding site of NQO1 and 
making its binding simply inefficient. However, since we have observed that NQO2 does 
bind NADH, there is also the possibility that these residues facilitate certain binding 
positions for NADH within NQO2 that is inefficient for electron transfer. This could 
certainly help explain why NQO2 seems to stay reduced by NADH for an extended period 
of time, as we observed by the colour change of the NQO2 crystal upon soaking with 
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NADH. Perhaps NADH can act as a weak competitive inhibitor for NQO2, which needs to 
be overcome by a certain concentration of NRH in the cell. Exploring whether or not this is 
true could be performed with more kinetics experiments focused on inhibition of NQO2. 
Since this hypothesis also suggests that the reason the quintuple mutant was much more 
efficient because it eliminates prolonged binding of NADH in the binding site, a future 
experiment investigating this would be crystallization of the mutant and examining whether 
the extended reduced state with NADH occurs with the mutant as well. If it is true that the 
quintuple mutant eliminated prolonged binding of NADH, we would expect to see a rapid 
reversion of the colour of the crystal, if any change does occur. This can also be measured 
as a change in absorbance at 450 nm. 
 One thing to consider is that we did not observe the full molecule of NADH in the 
crystallization experiment, therefore we have not been able to ascertain whether the tail of 
the NADH molecule binds in a large spectrum of positions, or if the molecule broke down 
at the bond between the ribose and nicotinamide. If these residues mutated are indeed 
facilitating a specific binding position for NADH, we would expect to see NADH in that 
position within the crystal structure. Since that was not the case, we could hypothesize that 
these residues are facilitating a broad spectrum of NADH binding by prohibiting the 
optimal position for electron transfer that would be seen in NQO1. 
When comparing the catalytic efficiency from the kinetics experiment to the literature 
values, there is a rather significant difference in the results obtained for wildtype NQO2. 
Previous work has cited a kcat/Km of 1,666 M-1 s-1 for NQO2 with NADH (23), which is 
over two orders of magnitude larger than the wildtype NQO2 value of 13 M-1 s-1 obtained 
from the kinetics experiment here. It is not fully clear why the experimental data did not 
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reproduce the literature value. However, a likely explanation would be the fact that the 
aforementioned study used a different assay to determine these values, using DCIP as an 
electron acceptor as opposed to menadione and MTT. In addition, the previous study did not 
mention what temperature the kinetics were performed. If it was at 37°C compared to our 
experiments at 20 °C, it is logical that the previous work reported significantly higher 
catalytic numbers. We can reasonably eliminate low enzyme activity as the reasons for this 
observation, since the purification was shown to be highly successful with no sign of 
misfolded protein or impurities. Repeating the experiments under the same assay and 
conditions as the aforementioned study would be a suitable pursuit for reproducing the 
literature values.  
 The fact that we were not able to observe saturation for the mutants compared to the 
wildtype NQO2 was unexpected. It raises the question of whether this is due to the Km(app) 
and kcat(app) rising significantly due to the mutations compared to the wildtype, or if there is 
an assay-related issue causing menadione and/or the MTT dye to continue getting reduced. 
Since the same assay was performed in the wildtype as well as NQO1 with no apparent 
problems in saturation, and there was no sign of non-enzymatic reduction observed in 
control tests, the first line of reasoning would not include an issue in the assay itself. For 
troubleshooting whether this is an assay-related phenomenon, the best course of action 
would be to repeat these experiments using a different kinetics assay. This could be done by 
using a different dye such as DCIP in order to measure reduction. If there are similar results 
observed with a different assay, this would show evidence that these observations are 
indeed due to the enzymes’ catalytic rates. There is also the option of circumventing the 
complications arising from multi-step kinetics assays by performing a direct reduction assay 
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using stopped-flow techniques to measure the rate of reduction of the enzymes by the 
cofactor (NADH or NRH) itself. This method would give the most direct answer to whether 
the mutations have caused the enzyme to be more efficiently reduced by the cofactor, 
however it would not give the complete picture of the overall turnover rates of the enzyme. 
If we assume the assay works as intended with the mutants then we can rationalize these 
high saturation levels by the fact that the Km(app) and kcat(app) values have significantly 
increased due to these mutations. If the kcat increases that means that the enzyme turns over 
a higher number of substrate molecules per second. However if the Km increases that may 
indicate lowered affinity for the substrate. Therefore, it is possible that these mutations have 
broadened the specificity of the NQO2 binding site by allowing it to turnover NADH more 
efficiently at the cost of its already weak affinity towards it. Another possibility for seeing 
higher Km(app) and kcat(app) for the mutants is if they resulted in an increase of the dissociation 
rate of NADH. This would increase the perceived kcat(app) due to the enzyme being refreshed 
for catalysis at a quicker rate, which may also result in a higher Km(app) value. Since we have 
seen some evidence towards prolonged binding of NADH within the binding site of NQO2, 
it is conceivable that the mutations have eliminated the molecular determinants facilitating 
prolonged binding of NADH (therefore resulting in higher rates of both cofactor 
dissociation and substrate turnover) without including the determinants of high affinity for 
NADH. This suggests that the mutations chosen have eliminated the aspects of NQO2 that 
cause prolonged binding of NADH and subsequent inefficiency utilizing it, but have not 
included the residues in NQO1 which facilitate its high affinity for NADH. It seems quite 
likely that these mutation have moved the mutant in the desired direction for shifting the 
cofactor specificity towards NADH. It is important to note that the kcat/Km I have observed 
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for NQO1 with NADH was approximately 8.24 x 105 M-1 s-1, which is expected of an 
efficient protein using its native cofactor. This value is three orders of magnitude greater 
than the catalytic efficiency of the quintuple mutant (918 M-1 s-1), which puts into 
perspective the fact that much more fine-tuning on the mutant NQO2 is needed to achieve 
catalytic efficiency with NADH similar to that of NQO1.If we wish to create an NQO2 that 
utilizes NADH with high affinity, there likely are more mutations needed to reach that goal. 
If the dissociation rate of NAD from the active site is what causes NQO2 to utilize 
NADH inefficiently, this can be examined through analysis of its inhibition of NQO2 
function. If NAD is also included in an enzymatic assay of NQO2 then its K i can be 
determined, which could reveal whether it significantly inhibits the enzyme at higher 
concentrations. If NAD does indeed inhibit the protein then it would be by competitive 
inhibition, so the substrate used for inhibition enzymatic assays may be required to have 
comparably low affinity, such as NADH, as opposed to the native substrates for NQO2 
(NRH or its analogues). Performing the assay with very low concentrations of NRH or an 
analogue may also produce a suitable analysis. There is a possibility that inhibition assays 
with NAD may not yield accurate results because it could be that NAD itself does not enter 
and inhibit the active site the same way as when it is already there after getting oxidized in 
situ. However, based on the assumptions derived from the collected data, an inhibition assay 
has the potential to reveal the real reason for why NQO2 is inefficient with NADH 
compared to NRH. 
Tying these kinetics results to the proposed NADH binding model informed by the co-
crystallization experiment with NADH (Figure 24), it is conceivable that the residues that 
were chosen for mutation participate in favorable interactions with the adenosine 
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diphosphate section of NADH. They are in close proximity to the adenosine diphosphate 
portion of the modelled NADH; their interactions with NADH could be causing its 
dissociation rate to be low, and hindering turnover efficiency. Since the catalytic rates of the 
quintuple mutant must be significantly higher before reaching levels comparative to NQO1, 
there is likely more residues involved in determining cofactor specificity that need to be 
targeted for future mutagenesis. 
The results observed regarding the cofactor specificity of NQO2 with this site-directed 
mutagenesis approach was more effective than simply removing/adding the C-terminal 
portion found in NQO1. This confirms that the factors determining the two proteins’ 
cofactor preference are subtle and residue specific. Future work on fine tuning the mutant 
should include a similar site-directed approach. 
4.3.2.1 Alignment of NQO1 and NQO2 sequences showing 
conservation at the chosen mutation sites  
Since the quintuple mutant had a significantly bigger effect on the catalytic efficiency of 
NQO2 than the triple mutant, it raised the question of which of the mutated residues plays 
the largest role in determining the cofactor specificity of NQO2. In an attempt to shed some 
light on this matter, a sequence alignment of 12 NQO2 and 17 NQO1 sequences from 
vertebrates was performed. This was done to observe whether levels of sequence 
conservation at all five residues sites aligns with these residues being important for enzyme 
function, and the changes in catalytic rates observed. This information is relevant for future 
fine tuning of the mutations made to observe larger effects on catalytic rates. Generally 
speaking, the alignment showed lower levels of conservation at those five residue sites in 
NQO1 (Figure C- 1, Appendix C) than the corresponding ones in NQO2 (Figure C- 2, 
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Appendix C). The alignment output summary for NQO1 and NQO2 alignment is shown in 
Table 6 and Table 7, respectively. The top two residues by percent frequency are listed for 
each site. In addition, the conservation score for each residue position is shown, which 
assign a numerical value to the level of physicochemical properties conserved at that site. A 
maximum score of 10 indicates conservation of all properties (67). 
Table 6: Output summary from alignment of NQO1 sequences 
NQO1 
Residue in H. sapien Q66 V72 G122 Y128 G193 
Top two residues by 
percent frequency 
N 23%     
K 17% 
G 35%      
A 17% 
G 29%     
Q 29 % 
Y 52%      
L 23% 
G 64%       
R 11% 
Conservation score 3 2 3 6 3 
 
Table 7: Output summary from alignment of NQO2 sequences 
NQO2 
Residue in H. sapien N66 H72 Q122 I128 E193 
Top two residues by 
percent frequency 
N 84%     
H, S 8% 
W 41%      
H 33% 
Q 91%     
R 8 %     
F 58%       
I 33% 
E 92%       
D 8% 
Conservation score 4 6 8 8 9 
 
The highest levels of conservation was seen for E193 in NQO2, suggesting that this 
residue is important for NQO2 function. Since this residue participates in a hydrogen bond 
with N66 that is not present in NQO1, this supports that this hydrogen bond is a key player 
in the cofactor specificity of NQO2. This is in line with the significant change in catalytic 
rates observed by the quintuple mutant, where this H-bond was removed through the N66Q 
and E193G mutations. Its H-bond partner N66 is not very well conserved in terms of its 
physicochemical properties, however, despite whether the residue present at that site is N 
(the vast majority), the two alternative residues seen can also participate in hydrogen 
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bonding (H and S). Therefore, if future mutants are created for the purpose of changing the 
cofactor preference of NQO2 to NADH, N66 and E193 should be included. I128 and Q122 
also showed strong conservation in NQO2, and although NQO2-trp did not show as much 
of a pronounced effect on the catalytic efficiency as NQO2-qtp, these residues could be 
synergistically controlling the cofactor specificity of NQO2 alongside the E193-H66 H-
bond. Deciding whether future mutation experiments should include Q122G and I128Y 
should be addressed by creating a double mutant that only contains E193G and N66Q and 
comparing that mutant’s kinetics to those of the quintuple mutant. As for H72, it does not 
appear to be a relatively strong player in NQO2 function based on its levels of conservation. 
It is also worthy of note that these five residue sites are poorly conserved in NQO1, 
which suggests that trying to change the cofactor specificity of NQO1 to NRH by 
performing the reverse mutations will not yield as much of a pronounced effect on its 
preference. It seems that throughout evolution NQO2 has diverged to contain these residues 
to direct its specificity towards NRH, but the residue sites themselves do not contribute 
much to NADH binding and specificity in NQO1. 
4.4 Future research 
The results from this project certainly help illuminate what is responsible for the 
preference of NQO2 for NRH over NADH, but there is still further analysis that must be 
done in order to achieve full characterization. Most importantly, the same kinetics 
experiments performed using NADH should be repeated with NRH (or a suitable analogue). 
Although the oxidized form (NR) can be readily obtained, the reduced form was not a 
commercially available product and needed to be synthesized in-house. Repeating the 
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kinetics experiments with NRH on the five proteins will fully reveal whether the mutations 
shifted the cofactor specificity of NQO2 from NRH to NADH, rather than simply increasing 
its efficiency using NADH. There is also the possibility that the mutations simply 
broadened the binding site’s range of acceptable cofactors, as opposed to making it specific 
towards NADH. Performing the kinetics with NRH may reveal whether that is the case, if 
the efficiency with NRH remains close or even better than the wildtype. If the cofactor 
specificity shifted towards NADH, the expected results would be an overall lower catalytic 
efficiency using NRH in the mutants compared to the wildtype. If the mutant successfully 
shows a shift from NADH to NRH, then additional mutation sites can be included in order 
to attempt shifting the specificity further towards NADH, mimicking the catalytic 
efficiencies found in NQO1.  
If a mutant that utilized NADH with high efficiency is successfully created, it is 
important to consider inhibition of the mutant protein by distinct NQO1 and NQO2 
inhibitors. If the mutant NQO2 shows less inhibition by NQO2 inhibitors and higher 
inhibition by NQO1 inhibitors, this could indicate that the mutations are making the protein 
very similar to NQO1. Since the overarching goal is to open doors for in vivo studies 
surrounding the function of NQO2 in the cell, creating a protein that ultimately functions 
like NQO1 would counter these efforts. This can also be addressed by kinetic assays using 
unique substrates for NQO1 and NQO2 on the mutants, and determining how the mutations 
have changed the substrate specificity of the enzyme. 
A mutant NQO2 that utilizes NADH efficiently while retaining NQO2 functionality 
would be a great tool for characterizing the role of NQO2 in the cell. If wildtype NQO2 is 
replaced by the mutant in a living cell, its levels of activity would be known since the 
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NAD(P)H levels in a cell are well characterized. The resulting phenotype, especially from 
fluctuating NAD(P)H levels can be analyzed with certainty that NQO2 is active. Since 
previous research has established connections of the proteins to anti-malarial drug 
mechanism and p53 pathway, cell lines that are used to manipulate these signaling pathways 
would be a good start.  
4.5 Conclusion 
The project’s main goal was to shed some light on what elements affect the cofactor 
preference of NQO2 for NRH, a unique cofactor, over NADH. In doing so, the objective 
was to ultimately help address the signaling role of NQO2 in the cell, which seems to go 
beyond its detoxification pathway through reduction of quinones. The project’s results 
showed that NQO2 and NQO1 have different binding stereochemistry than other 
flavoenzymes utilizing a nicotinamide-based cofactor, which reinforced the need to 
characterize their unique mode of binding. By attempting to shift the specificity of NQO2 
from NRH to NADH through site-directed mutagenesis, the results show that the residues 
mutated significantly influence catalytic efficiency using NADH. This sets up a good 
foundation for further characterizing of the effect of the mutations on efficiency using NRH, 
and whether the mutations have partially or fully achieved the intended effect. The results 
also suggest that the mutations may have broadened the specificity of the enzyme as 
opposed to a shift in preference, which opens the door for further investigation and more 
potential mutations. Ultimately the project has resulted in forward momentum towards 
characterizing the molecular determinants of the cofactor specificity of NQO2, and creating 
a mutant NQO2 that can be utilized in vivo to determine its role in cell signaling. 
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Appendix A: Alignment of wildtype human NQO1 and NQO2 
sequences 
An alignment of human NQO2 and NQO1 sequences in Jalview showing the percent identity 
between the two proteins’ amino acid sequence. 
 
 
 
Figure A- 1: Alignment of human NQO1 and NQO2 illustrating percent sequence identity 
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Appendix B: Alignment of wildtype NQO2 with sequenced NQO2-
trp and NQO2-qtp after site-directed mutagenesis 
 
Figure B- 1: Alignment of wildtype NQO2 with sequenced triple mutant (NQO2-trp) after 
third round of site-directed mutagenesis 
The mutations correspond to Q122G, H72V, I128Y, and were introduced using QuikchangeTM 
mutagenesis protocol. 
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Figure B- 2: Alignment of wildtype NQO2 with sequenced quintuple mutant (NQO2-qtp) 
after final round of site-directed mutagenesis 
The mutations correspond to Q122G, H72V, I128Y, E193G and N66Q and were introduced 
using QuikchangeTM mutagenesis protocol. 
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Appendix C: Alignment of NQO1 and NQO2 sequences showing 
conservation and consensus residues at the chosen mutation 
sites 
 
Figure C- 1: Alignment of NQO1 sequences showing conservation and consensus at the 
five chosen residue sites 
Sequence alignment of 17 vertebrate NQO1 residues showing conservation and consensus 
sequence at the five residue sites corresponding to the chosen mutation sites from NQO2. 
Aligned with Muscle (68). Calculation of conservation score, consensus sequence and 
illustration performed in Jalview (69). Thick vertical green lines indicate hidden stretches of 
sequence. 
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Figure C- 2: Alignment of NQO2 sequences showing conservation and consensus at the 
five chosen mutation sites 
Sequence alignment of 12 vertebrate NQO2 residues showing conservation and consensus 
sequence at the five residue sites corresponding to the chosen mutation sites. Aligned with 
Muscle (68). Calculation of conservation score, consensus sequence and illustration performed 
Jalview (69). Thick vertical green lines indicate hidden stretches of sequence. 
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